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1. Summary: 
 
Acute pancreatitis is a debilitating inflammation of the pancreas, which leads to exocrine dysfunction; in its 
severe form, the disease is associated with substantial morbidity and mortality. Following pancreatitis, the 
pancreas exerts some regenerative capacities: in particular, differentiated acinar cells are able to re-enter the 
cell cycle and start to proliferate. However, the extent of pancreatic regeneration is limited; therefore, 
elucidating the molecular mechanisms that drive pancreatic regeneration and boost this process is a major focus 
of research. Thyroid hormones (TH) are important homeostatic regulators of several biological processes, 
including regenerative responses. Recently it was observed that TH promote pancreatic acinar cell proliferation 
in adult rodents, without induction of damage or inflammation.  
In the present project, we sought to investigate whether TH are involved in pancreatic regeneration, and if non-
physiological TH levels alter acinar cell proliferation following acute pancreatitis. Moreover, we aimed to 
characterize the molecular mechanisms of the mitogenic activity of T3, the biologically active TH, on adult acinar 
cells. 
To this aim, we used the well-established model of serial cerulein injections to induce acute pancreatitis, we 
altered TH levels in vivo in both a systemic (hypothyroidism or thyrotoxicosis) and tissue specific manner in 
genetically modified animals and investigated how TH-related parameters in the pancreas intersect with 
pancreatic regeneration following inflammatory injury of the tissue. 
We found that TH are locally activated at the onset of acute pancreatitis and local hyperthyroidism triggers acinar 
cell proliferation.  Characterization of altered TH levels in vivo highlighted a positive correlation between TH 
levels and number of proliferating acinar cells, which was further demonstrated by the use of an animal model 
of increased pancreatic TH levels. Moreover, we observed that TH influence acinar cell proliferation 
independently of tissue damage or inflammation. The investigation of the molecular mechanisms of T3 induction 
of acinar cell proliferation revealed the involvement of Akt, HDAC and TGF-β signaling.  
We concluded that activation of TH signaling is an initiating event that triggers pancreatic regenerative response, 
promoting acinar cell proliferation. Moreover, we observed that acute pancreatitis leads to a systemic decrease 
in circulating TH, which may contribute to the worsening of the disease. Overall, the present study provides the 
foundation for the potential use of TH to boost pancreatic exocrine regeneration and suggests reduced thyroid 
function may impact pancreatic regeneration, in patients suffering from acute pancreatitis. Lastly, we propose 
that T3 exogenous administration is an efficient model to study acinar cell proliferation in vivo in the absence of 
pancreatic damage and inflammation. 
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1.1 Zusammenfassung 
 
Akute Pankreatitis ist eine schwächende Entzündung der Bauchspeicheldrüse, die zu exokriner Dysfunktion führt. 
In ihrer schweren Form ist die Krankheit mit erheblicher Morbidität und Mortalität verbunden. Nach einer 
Pankreatitis übt die Bauchspeicheldrüse einige regenerative Fähigkeiten aus. Insbesondere differenzierte 
Azinuszellen können wieder in den Zellzyklus eintreten und sich vermehren. Das Ausmaß der 
Pankreasregeneration ist jedoch begrenzt, weswegen die Aufklärung der molekularen Mechanismen, welche die 
Pankreasregeneration vorantreiben, ein wichtiger Forschungsschwerpunkt sind. Schilddrüsenhormone (TH) sind 
wichtige homöostatische Regulatoren verschiedener biologischer Prozesse, einschließlich regenerativer 
Reaktionen. Kürzlich wurde beobachtet, dass TH die pankreatische Azinuszellproliferation bei erwachsenen 
Nagetieren ohne Induktion von Schäden oder Entzündungen fördern. 
Im vorliegenden Projekt untersuchten wir, ob TH an der Pankreasregeneration beteiligt ist und ob 
nichtphysiologische TH-Spiegel die Azinuszellproliferation nach akuter Pankreatitis verändern. Darüber hinaus 
wollten wir die molekularen Mechanismen von T3, der biologisch aktiven TH, mitogener Aktivität auf adulten 
Azinuszellen charakterisieren. 
Zu diesem Zweck verwendeten wir das etablierte Modell serieller Cerulein-Injektionen, um eine akute 
Pankreatitis zu induzieren. Wir veränderten die TH-Spiegel in vivo sowohl in systemischer (Hypothyreose oder 
Thyreotoxikose) als auch in gewebespezifischer Weise (GMO-Tiere) und untersuchten, wie TH-bedingte 
Parameter in der Bauchspeicheldrüse sich mit der Pankreasregeneration nach einer entzündlichen Verletzung 
des Gewebes verhalten. 
Wir fanden heraus, dass TH zu Beginn einer akuten Pankreatitis lokal aktiviert ist und eine lokale Hyperthyreose 
die azinöse Zellproliferation auslöst. Die Charakterisierung der veränderten TH-Spiegel in vivo zeigte eine positive 
Korrelation zwischen den TH-Spiegeln und der Anzahl der proliferierenden Azinuszellen, was durch die 
Verwendung eines Tiermodells mit erhöhten Pankreas-TH-Spiegeln demonstriert wurde. Darüber hinaus 
beobachteten wir, dass TH die azinöse Zellproliferation unabhängig von Gewebeschädigung oder Entzündung 
beeinflusst. Die Untersuchung der molekularen Mechanismen der T3-Induktion der Azinus-Zellproliferation 
zeigte die Beteiligung von Akt-, HDAC- und TGF-β-Signalisierung. 
Wir folgern, dass die Aktivierung der TH-Signalgebung ein auslösendes Ereignis ist, welches die regenerative 
Pankreasresponse auslöst und die azinare Zellproliferation fördert. Darüber hinaus beobachteten wir, dass eine 
akute Pankreatitis zu einer systemischen Hypothyreose führt, die zur Verschlimmerung der Erkrankung beitragen 
kann. Insgesamt legt die vorliegende Studie Grundlagen für die mögliche Verwendung von TH zur Förderung der 
exokrinen Pankreasregeneration, und legt die klinische Beurteilung der Schilddrüsenfunktion bei Patienten mit 
akuter Pankreatitis nahe.  
  
4 
 
2. Introduction 
 
2.1 Thyroid hormones 
 
Thyroid hormones (TH) are important homeostatic regulators of several biological processes, which act on 
virtually any cell. The major product of the thyroid is thyroxine (L-3,5,3',5'-tetraiodothyronine, T4), however 
triiodothyronine (3,3',5-triiodo-L-thyronine, T3) is considered to be the active TH. TH play an important role 
during the whole life span of individuals across all vertebrates. Importance of TH during development as well as 
adult life is best recognized when aberrant thyroid function, thyrotoxicosis or hypothyroidism, are observed. 
Several conditions are associated with altered TH levels, among them cardiovascular diseases, obesity and 
diabetes [1]. Moreover, hypothyroidism during embryo development leads to aberrant organogenesis, 
particularly for the neural system [2]. 
As discussed in the following sections, production, transport and activity of TH are strictly regulated by multiple 
mechanisms that orchestrate TH control in both a systemic and a tissue specific fashion.  
 
2.1.1 Production and release of thyroid hormones 
 
The thyroid is the first glandular structure to form during human development and it becomes functional at 
approximately 10 weeks of gestation (~E15.5 in the mouse) [2]. It consists of two elongated lobules, connected 
by an isthmus, composed by cuboidal cells: the thyrocytes. Thyrocytes lay in spherical monolayers, the follicles, 
with their lumens filled with a clear protein-rich substance called colloid. Thyroid follicles are highly vascularized 
and surrounded by a connective capsule [3].  
Synthesis of thyroid hormones:  
The first step for the synthesis of TH is Iodine (I2) uptake; Iodide (I-) absorbed by the stomach and the intestinal 
tract is then transported to the thyroid, which stores about 80% of all body Iodide. Iodide is actively concentrated 
in the thyroid follicular cells by the action of the Iodine-Sodium-symporter (NIS); once in the cytosol, Iodide is 
transported in the colloid by the Pendrin transporter, which exchanges Iodide efflux with electroneutral 
exchangers (i.e. Cl-). At the interface between colloid and the apical membrane of thyrocytes, the enzyme 
thyroperoxidase (TPO) catalyzes the organification of Iodide by promoting its incorporation in tyrosine residues 
of a large precursor molecule named thyroglobulin (TG - >300KDa). Specifically, the thyroperoxidase requires the 
action of two dual oxidases enzymes DUOX1 and DUOX2: DUOX enzymes are responsible for the production, 
NADPH dependent, of H2O2, which is necessary for thyroperoxidase to oxidize Iodide (I-  I0). Oxidized Iodide 
reacts spontaneously with thyroglobulin, stored within the colloid, thereby producing monoiodinated-tyrosine 
(MIT) or diiodinated-tyrosine (DIT) residues. Thyroperoxidase together with H2O2 are responsible also for the 
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conjugation of two DIT residues or a MIT with a DIT thereby producing T4 and T3 residues. Thyrocytes incorporate 
mature TG within vesicles that are driven to the lysosome. After fusing with the lysosome, hydrolysis of 
thyroglobulin will generate T4 and T3 (and one alanine that is the link of TH to the backbone of thyroglobulin) 
which are released in the circulation. Importantly, MIT or DIT residues, as well as rT3,  that are not useful for the 
generation of TH are reabsorbed and recycled by the activity of the iodotyrosine dehalogenase 1 (DEHAL1), which 
catalyzes deiodination of the iodinated tyrosine. A schematic representation of TH synthesis is presented in Fig.1 
(Reviewed in [4]). 
 
Figure 1:  Schematic representation of thyroid hormone synthesis. Taken from [4]. 
 
Multiple signals define thyroid activity and therefore TH synthesis and release; this systemic control has been 
extensively studied and is referred as the hypothalamic-pituitary-thyroid axis.   
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Hypothalamic-pituitary-thyroid axis:  
Regulation of TH synthesis in the thyroid: Thyroid function and growth is intimately regulated by the Thyroid-
stimulating factor (TSH), which is produced by thyrotropic cells (also called thyrotropes) located within the 
pituitary gland. TSH is a glycoprotein composed of two subunits (α and β); the α-subunit is shared among 
different hormones released by the pituitary (i.e. vasopressin, oxytocin, GH, FSH and LH) while the β-subunit is 
specific for TSH [5]. TSH acts on thyroid follicular cells by binding to its own receptor (TSH-R): a G-coupled 
receptor able to transduce multiple signaling cascades. The main downstream signaling activated by TSH-R is the 
adenylate cyclase with consequent accumulation of cAMP [6]. The cAMP pathway in turn, induces transcription 
of key components of thyroid synthesis such as the Iodine-Sodium-symporter (NIS), thyroperoxidase (TPO) as 
well as TSH-R genes [5]. Furthermore, cAMP activates protein kinase A (PKA), which promotes thyrocytes growth 
and proliferation [7]. Recently, Selmi-Ruby et al. reported that the thyroid expresses all TH receptors, and specific 
removal of the TH receptor β isoform in thyrocytes dysregulates normal thyroid hormone synthesis, highlighting 
the existence of an additional regulation of thyroid function by direct TH feedback [8]. 
Regulation of thyroid-stimulating factor (TSH) in the pituitary gland: Thyrotropic cells receive signals from the 
hypothalamus and the circulation to modulate the release of TSH. Circulating TH, for example, can enter 
thyrotropic cells in which they reduce both TSH release and production [9]. Thyrotropic cells express TH receptors 
as well as deiodinases (DIO, enzymes able to catalyze deiodination of TH, see further); of notice, expression of 
deiodinase type-II (DIO2), responsible for intracellular T4T3 activation, amplifies TH negative feedback 
ensuring proper synthesis and release of TSH [10]. Furthermore, TH downregulate expression of Thyrotropin-
releasing hormone receptor (TRH-R) and promote its degradation reducing the stimulatory signal sent out by the 
hypothalamus [11]. TRH is a tripeptide (Glu-His-Pro) produced by neurons in the paraventricular nucleus of the 
hypothalamus, it upregulates TSH synthesis and induces fast release of TSH stored in vesicles [4]. Moreover, TRH 
acts as a trophic factor during thyrotropes development, promoting their growth and proliferation [12]. 
Importantly, aside from regulating transcription and secretion of TSH, TRH signaling promotes TSH glycosylation, 
which is required for proper TSH activity [13]. 
Regulation of Thyrotropin-releasing hormone (TRH) neurons in hypothalamic neurons: Within the 
paraventricular nucleus of the hypothalamus, thyrotropin-releasing hormone neurons release TRH in the 
pituitary-portal circulation. TRH release is controlled by several complex signals from the central nervous system, 
which integrates information about metabolism, body temperature, and cardiovascular function, as well as by 
circulating TH levels. TH are the main modulators of TRH synthesis: particularly, the TH receptor β2 (THRβ2) 
isoform represses TRH transcription as well as downregulates expression and activities of key enzymes involved 
in TRH maturation (i.e. PC1/3, [14]).  
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Figure 2: Schematic representation of the hypothalamic-pituitary-thyroid (HPT) axis. Adapted by [4]. 
 
In conclusion, the hypothalamic-pituitary-thyroid axis ensures proper synthesis and release of TH in the 
circulation by integrating multiple physiological signals. At the same time, circulating TH establish a negative 
feedback regulation with each member of the axis. Experimental models of disruption or dysregulation of many 
components have highlighted that, although compromised, this system “re-wire” to preserve physiological levels 
of TH [15]. 
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2.1.2 Thyroid hormones transporters: within the circulation and across membranes 
 
Because of their low solubility in water, once in the circulation T4 and T3 travel bound to proteins. The liver is 
the main producer of TH carrying proteins: thyroxine-binding globulin (TBG) and transthyretin (TTR, also known 
as pre-albumin) [1]. Furthermore, due to its high concentration in the circulation, Albumin (ALB) is also able to 
carry TH [16]. Most TH travel bound to TBG (~75% of T4), which shows higher affinity to TH than TTR. The amount 
of circulating TH-transporters is highly variable between individuals [17], especially humans, which renders the 
quantification of total-T4 (T-T4) and total-T3 (T-T3) hormones a valid measurement of thyroid function only when 
the amount of TH-transporter does not change. A more reliable measurement of thyroid function is indeed the 
quantification of free-T4 and free-T3 (F-T4 and F-T3), which does not account for the abundance of TH-
transporters [18]. Moreover, the F-T4 and F-T3 levels reflect the percentage of TH available to enter cells; in fact, 
the large amount of TH bound to proteins is thought to serve as a buffer to secure availability of TH throughout 
the body [19]. When looking at early embryo TH levels for example, T-T4 is approximately 100 times less than 
physiological levels; however, measurement of F-T4 show values in the order of its biological activity. This is due 
to the very low abundance of circulating TH transporter during early development [20].  It is important to mention 
that the binding capacities of TH transporters can be modulated by several conditions such as pH or post-
translational modifications (PTMs), which in turn may constitute an additional mechanism of controlling local TH 
availability [21]. 
It was originally postulated that TH could freely cross the cell membrane because of their lipophilic nature. 
However, pioneering studies by Christense [22] in vitro that highlighted the requirement of ATP for TH uptake in 
ovarian cancer cells and by Schwartz in vivo [23] that showed that TH are up-taken at different rates between 
tissues, suggested the presence of specific transporter mechanisms. Up to now, many TH membrane transporters 
have been identified, of which some of the best-characterized classes are: the organic anion polypeptides 
transporters (OATPs) (reviewed in [24]), the monocarboxylate transporters (MCT) (Reviewed in [25]), and the 
heterodimeric amino acids transporters (HATs) (Reviewed in [26]). OATPs are part of a large family of 
multispecific transporters, most of which are expressed in liver and kidney where they participate in processes 
such as detoxification [27]. Different OATPs can transport TH across the cell membrane; among them the OATP14 
(OATP-F in humans) is of particular interest for its role in the brain. OATP14 shows high affinity to T4 (but not T3) 
and it is highly expressed in the brain vascular system where it controls the delivery of T4 across the blood-brain 
barrier [28]. The LAT1 and LAT2 transporters belong to the HATs family; the work of Ritchie et al [29] in Xenopus 
l. oocytes as well as in mammalian cells demonstrated that they efficiently transport TH. Interestingly, among 
others transporters, LAT1 and LAT2 are widely expressed across the body, which suggest that they could 
determine most of TH transport across the membrane [26].  Of all the MCT transporters, mainly MCT8 and MCT10 
are specific TH transporters [30]. The MCT8 gene has been extensively studied because mutations in this gene 
are associated with mental retardation. Indeed, mice carrying MCT8 mutations show major defects in neural 
development, which correlate with severe brain-hypothyroidism [31]. In fact, MCT8 is required for both influx 
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and efflux of T3 in neurons, thereby determining the proper TH concentrations and diffusion during brain 
development; of note, other organs seem to be spared by MCT8 dysfunctions.  
 
2.1.3 Intracellular regulation of thyroid hormones: the deiodinases family  
 
Virtually any cell is able to regulate intracellular TH concentration by modulating expression and activity of TH 
transporters and deiodinases (DIO) enzymes. Deiodinases catalyze the mono-deiodination of TH on either the 
outer ring (outer ring deiodination: ORD) or the inner ring (inner ring deiodination: IRD), contributing to both 
activation and inactivation of TH (T4  T3 and T4rT3, T3  T2 respectively – See figure 3). Three different 
deiodinases have been identified in both rodents and humans (DIO1-2-3). All deiodinases are integral membrane 
proteins that share a similar catalytic site, the thioredoxin fold, which contains the special amino acid 
Selenocysteine (Sec). The Sec amino acid is coded by UGA, which is usually “read” as a stop codon; however, the 
presence of a specific 3D loop structure, the SECIS element, present in the 3’UTR of the messenger RNA allows 
the insertion of this special amino acid (figure 4) [32].  
 
 
Figure 3: Mechanism of action of deiodinases enzymes.  
(Note that here deiodinases are ascribed as D1-2-3) Taken from [32] 
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Figure 4: Schematic representation of Selenium-Cysteine (SEC) insertion. Briefly, during translation, the SECIS 
element encoded in the 3’ of the deiodinase mRNA, folds into a stem-loop and promotes insertion of the SEC 
amino acid instead of the stop-codon UGA. Taken from [32]. 
 
Deiodinase type-I (DIO1) was the first deiodinase to be identified [33]; it is the only deiodinase able to catalyze 
both ORD and IRD reactions determining both activation and inactivation of TH. DIO1 is expressed in several 
organs such as liver, kidney, muscle and the thyroid [34]. It is well accepted that DIO1, particularly in the liver, is 
responsible for most peripheral T4T3 conversion [35], however its high preference for rT3 and sulfated TH (see 
further: TH catabolism) suggests that it may participate in the catabolism of TH and serve as a scavenger of excess 
TH [32]. DIO1 expression is regulated by multiple factors, including TH themselves (a TRE element on the 
promoter was identified, see further). It localizes specifically on the plasma membrane with the catalytic site 
towards the cytosol, however retention in the ER has also been observed (i.e. in the liver [36]). Mice lacking DIO1 
(DIO1KO) show elevated T4 and rT3 levels while T3 concentrations remain unchanged, arguing its importance in 
peripheral TH activation [34]. Interestingly, analysis of TH excretion highlighted a marked increase of TH in feces 
of DIO1KO animals suggesting the involvement of DIO1 in recycling iodine.  Deiodinase type-II (DIO2) is the main 
intracellular activator of TH (T4  T3); its expression increases during hypothyroidism while T4 and rT3 act as 
potent inhibitors of DIO2 activity [32]. Importantly, DIO2 is retained in the ER, with the catalytic site exposed to 
the cytoplasm: this specific localization allows the newly generated T3 to access the nucleus without being 
inactivated by other deiodinases. Multiple factors regulate DIO2 gene expression: among others, cAMP signaling 
has been described to play a major role in promoting DIO2 expression in different organs, particularly brown 
adipose tissue (BAT) [37, 38]. Aside from the transcriptional control, DIO2 activity is regulated at a 
posttranslational level by binding to T4: precisely, DIO2 shows a half-life of ~45min, and presence of T4 
accelerates DIO2 degradation. Steinsapir demonstrated that this regulation depends on the proteasome activity; 
indeed, further studies have highlighted that substrate interaction (particularly T4) promotes DIO2 ubiquitination 
thereby impeding excessive T3 production [32, 39]. Animal models of DIO2 deletion (DIO2KO) show normal T3 
levels but elevated T4 and TSH; as previously mentioned, this can be explained by the absence of DIO2 in pituitary 
cells where T4T3 conversion amplifies TH feedback downregulating TSH production [34]. Moreover, as 
observed in hypothyroid animals, lack of DIO2 in BAT impairs adaptive thermogenesis ([40], see further action of 
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TH in metabolism). Surprisingly, no major alterations were observed with regards to cognitive functions, arguing 
the importance of DIO2-dependent T3 activation during brain development. Type-III deiodinase (DIO3) is 
responsible for inactivating T3 (T3T2) and preventing T4 activation (T4rT3); of all the three deiodinases DIO3 
is the only to have an intronless and imprinted gene structure [41]. DIO3 localizes on the plasma membrane with 
its catalytic site directed towards the cytosol [42]; because of this specific localization DIO3 expressing cells are 
able to reduce TH influx and maintain a hypothyroid state independently of circulating TH levels. Baqui and 
colleagues have highlighted that DIO3 can be re-internalized within vesicles, in a clatrin dependent mechanism 
[43], while Jo and collaborators showed that DIO3 can be found in the nucleus of neurons [44], suggesting the 
existence of a complex regulation of DIO3 localization. DIO3 is expressed in multiple tissues (i.e. brain, skin, liver) 
where it attenuates TH stimulation; in the placenta, for example, DIO3 activity prevents excessive transfer of 
maternal TH towards the embryo. Interferences with placenta-DIO3 activity lead to abnormal embryonic 
development due to thyrotoxicosis [45, 46]. Interestingly, DIO3KO animals are hypothyroid but show normal TSH 
levels. Although still poorly understood, a possible explanation for this is that DIO3 may protect the 
hypothalamus from thyrotoxicosis, ensuring proper TRH production (TH inhibit TRH secretion, see previous 
section) [4]. Recently a great interest towards DIO3 has been evoked by multiple observations that DIO3 
expression is often found in cancer cells (see further TH and cancer). 
In conclusion, deiodinases ensure a fine regulation of intracellular TH. As it will be discussed in the next section, 
local availability of TH together with tissue specific distribution of TH receptors define a cell-specific transduction 
of TH signaling.    
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2.1.4 Thyroid hormones activity: between genomic and non-genomic actions 
 
Within the cell, TH regulate several cellular processes; most TH signaling occurs via binding of TH with their TH 
receptors (THR) and consequent transcriptional regulation, a process named genomic action of TH. TH receptors 
belong to the nuclear receptor superfamily (NR) and they bind to specific DNA sequences: the Thyroid Response 
Elements (TRE) [47]. TH receptors share a conserved structure with other NR, consisting of a variable N-terminal 
domain, a DNA binding domain (DbD), a hinge region and the C-terminal domain, which allows ligand binding 
and receptor dimerization. Two genes encode for TH receptors in all mammals: TH receptor α (THRα) and TH 
receptor β (THRβ) [48]. Each gene produces different isoforms that vary for ligand-binding capacities, tissue 
distribution, and function (see figure 5). TH receptors act as homodimers or heterodimers by binding other 
nuclear receptors such as the Retinoic X receptor (RXRs). Although still poorly investigated, the specific homo- / 
heterodimers that are formed contribute to define the specificity and the degree of TH receptor transcriptional 
regulation. It follows that the relative abundance of each transcription factor constitutes an additional regulation 
of TH signaling [49, 50].  In contrast to classic steroid receptors, TH receptors are able to modulate transcription 
also in a ligand-independent manner. Particularly, un-ligated TH receptor negatively regulate transcription by 
recruiting corepressors (N-COR-SMRT-HDAC) while binding to TH favors the displacement of the repressor 
complex and recruitment of coactivators (SRT-HAT) [47]. – Represented in figure 6 - Exceptions to this model are 
genes negatively regulated by TH. The proposed mechanism for this regulation involves a specific DNA sequence, 
the “negative”-TRE (nTRE): binding of TH ligated TH receptor to nTRE generates a different TH-THR-DNA complex 
conformation that favors corepressors recruitment and consequent ligand dependent repression of 
transcription. An example of this is the regulation of the thyroid-stimulating factor (TSH-) β subunit promoter, 
which is negatively regulated by TH as a component of the negative feedback loop that controls the 
hypothalamus-pituitary-thyroid axis [51].  
 
 
  
13 
 
 
 
 
 
Figure 5: A) Table illustrating the different isoforms identified for Human and mouse TH receptor genes (Taken 
from [4]). B) Respresentation of TH receptor modulation of transcription on thyroid hormone response 
elements (TRE). (Taken from [51]) 
 
Although it was initially postulated that TH act solely as transcription modulators, several evidences have been 
collected which demonstrate that TH regulate several biological processes independently of transcription [52]. 
These non-genomic actions of thyroid hormone often involve TH receptors, furthermore they can be initiated 
on the cell membrane by the integrin αVβ3 (recently reviewed in [53]). The αVβ3 is a membrane receptor that 
mediates interaction with the extracellular matrix (ECM, i.e. laminin); it shows two binding sites for TH, one for 
T4 and T3 respectively; binding of TH activates multiple intracellular signaling in a ligand specific manner (T4 or 
T3 specific). Davis and coworkers have extensively characterized the signaling cascades transduced by αVβ3; 
most of these analyses used particulate analogs of TH (i.e. agarose-T4), which are excluded from the cytoplasm, 
allowing the selective study of signaling triggered on the plasma membrane. A schematic representation of 
actions initiated by the αVβ3 integrin receptor can be found in figure 6. As mentioned before, within the 
cytoplasm binding of thyroid hormone to TH receptors can regulate different pathways at a post-translational 
level. Some of the best characterized examples involve the regulation of Pi3k-Akt signaling cascade by binding 
A 
B 
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of TH receptor α or β to the p85 subunit and the crosstalk with the Wnt signaling by interaction of TH receptors 
with β-catenin (Reviewed [54]). It is worth mentioning that TH regulation of these pathways often transduces 
different cellular processes in a cell specific manner. In summary, as shown in figure 6, TH act on several cellular 
processes defining a complex regulation of cellular behavior.  
 
 
 
 
Figure 6: Schematic representation of nongenomic actions of thyroid hormones. To note, in the present 
representation particular focus is given to TH actions transduced trough the integrin αVβ3. Taken from [55]. 
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2.1.5 Metabolism of thyroid hormones 
 
Aside from the deiodination of TH catalyzed by deiodinases enzymes, TH are subjected to different modifications 
in order to modulate their catabolism and activity. Two main modifications have been described in both humans 
and rodents: sulfation and glucoronidation (Reviewed in [56]). Both sulfation and glucoronidation of TH are 
reversible modifications that increase solubility and direct TH for degradation and excretion; importantly, 
sulfated-TH as well as glucoronidated-TH do not show binding capacities to TH receptors and are therefore 
considered biologically inactive [57]. Sulfotransferase enzymes are mainly expressed in the liver. Among them 
they show a conserved preference for TH substrates (T2>T3≈rT3>T4) [57]. Sulfated-TH are the primary substrates 
for DIO1 activity, which catalyzes their deiodination, contributing to iodine recycling [58, 59]. Glucoronidation is 
a common modification observed to increase solubility of several compounds, in the liver glucoronidation of TH 
drives glucoronidated-TH for biliary- fecal excretion. It is important to mention that hydrolysis of sulfated- or 
glucoronidated-TH within the intestine may serve as a pool for reabsorption of active TH. Although deiodination, 
sulfation, and glucoronidation are the main TH modifications, also decarboxylation or deamination of the alanine 
side chain have been observed [56]. Decarboxylation of TH produces iodothyronamines, while deamination leads 
to the acetic acid TH analogues (i.e. TRIAC and TETRAC). These compounds show thyromimetics activities, 
however still little is known about their biological importance. Of note, the interest towards this class of 
compounds is rising over the last years because of their potential clinical use. TRIAC for example, show high 
binding specificity towards TH receptor β1 isoform and is able to cross the brain blood barrier in a MCT8 
independent way, for this reason it is currently under evaluation for the treatment of subjects with MCT8 
mutations [1]. 
 
2.1.6 Thyroid hormones’ actions 
 
As described in the previous sections, an intricate regulation of TH transporters, receptors, deiodinases, and 
other factors orchestrate TH signaling in a cell specific manner. This in turn, may explain the pleiotropic effects 
driven by TH during development as well as adult life. Even before completing thyroid development, the embryo 
actively responds to maternal TH, which can be detected as early as E11.5 – E12.5 in the mouse ([60], G5.6W in 
humans [61]). Proper maternal TH is indispensable for a variety of developmental processes, particularly 
neurogenesis [2]. Clinical conditions of maternal hypothyroidism during pregnancy are associated with mental 
retardation and cretinism [20]. In the following sections, examples of TH action will be discussed. In particular, 
the topics chosen as examples cover TH involvement in regenerative and homeostatic signaling, metabolism, and 
cancer.  
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2.1.6.1 Thyroid hormones and regulation of metabolism  
 
TH are important modulators of metabolism, their pleiotropic actions on key metabolic organs, such as liver or 
muscles, as well as modulation of the nervous system regulate body energy expenditure and thermogenesis. In 
this section, examples of TH action on metabolism will be discussed briefly, however it is important to mention 
that many actions of TH remain elusive and further studies are needed to characterize their intricate regulatory 
network. TH increase body energy expenditure and oxygen consumption, one reason for this effect is the 
stimulation of Ion gradients across membranes and consequent increase of ATP usage [40]. Indeed, TH stimulate 
activities of the Na+/K+/ATPase on the plasma membrane [62] and the Ca2+ gradient between cytoplasm and 
sarcoplasmic reticulum within the skeletal muscle [63, 64]. Moreover, TH are important regulators of adaptive 
thermogenesis, this is highlighted by the observation that hypothyroid individuals are cold intolerant while 
hyperthyroid ones do not tolerate heat. Their regulation of adaptive thermogenesis mainly involves actions on 
the brown adipose tissue (BAT) and the skeletal muscle. BAT is the main tissue responsible for adaptive 
thermogenesis in rodents (and newborns humans), its development and function is dependent on the synergistic 
activities of TH and the sympathetic nervous system (SNS). Within the BAT, heat is generated by uncoupling ion 
gradients from the oxidative phosphorylation and consequent release of energy as heat; this proton leakage 
occurs on the inner mitochondrial membrane in the presence of Uncoupling protein 1 (UCP1). TH regulate 
expression levels of UCP1 in brown adipocytes in a TH receptor β dependent manner, however studies using 
selective TH receptor β agonist revealed that this TH receptor β-dependent action is not sufficient to sustain 
adaptive thermogenesis [65]. Indeed, TH receptor α-KO animals have impaired thermogenesis, which suggests 
that also the isoform α participates in this process, probably by supporting SNS stimulation of the BAT (Calcium 
gradient) [66]. Importantly, intracellular activation of TH via deiodinase type-II (DIO2) activity is required to 
generate proper TH response within brown adipocytes; DIO2KO animals are in fact cold intolerant and only T3 
replacement (not-T4) stimulates BAT activity [67]. Recently, a great interest towards TH action on the adipose 
tissue has been generated by the observation that white adipocytes can be converted to a more brown 
phenotype, “brite” adipocytes, characterized by expression of UCP1 and multilocular fat storage [68].  Although 
still poorly understood, by regulating BAT specification and function [69], TH may serve as potent stimulators of 
this brite adipocytes conversion [70]. Aside from regulating adaptive thermogenesis, TH can modulate nutrient 
metabolism. For example, TH regulate maturation and activity of pancreatic β-cells [71-74], as well as glucose 
transporter (GLUT4) in muscle and adipose tissue thereby contributing to glucose homeostasis [75]. 
Furthermore, TH regulate hepatic fatty acids and cholesterol synthesis and catabolism (Reviewed in [76]). Overall 
TH levels regulate multiple metabolic processes in different tissues; importantly, the CNS in turn, integrates 
several signals of the “metabolic state” and regulates TH synthesis and release accordingly.  
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2.1.6.2 Thyroid hormones in homeostatic and regenerative processes 
 
Participation of TH in orchestrating development of multiple organs has been observed for a long time; recently, 
an increased amount of evidences highlighted their continuous involvement in adult homeostasis as well as 
regeneration of many target tissues.  
The skin is an epithelial organ which shows high cellular turnover, TH promote epidermal differentiation and 
keratinocytes proliferation during fetal development [77]. Moreover, hypothyroidism leads to the manifestation 
of myxedema, characterized by aberrant deposition of glycosaminoglycan and formation of dermal edema. Effect 
of thyrotoxicosis on skin homeostasis is, on the other hand, still controversial. Safer and coworkers described the 
positive effect of TH on keratinocytes proliferation in vitro, moreover they highlighted the importance of local 
TH control by deiodinases within these cells, both in vivo and in vitro [78, 79]. These data are in agreement with 
what has been observed in mice lacking TH receptor α and β (or both), where keratinocytes proliferation was 
reduced in a similar manner as observed in hypothyroid animals [80]. However, depending on the route of 
administration, divergent results were obtained when TH effect was tested in vivo [81]. While topical application 
of T3 induced keratinocytes proliferation, confirming the positive effect, systemic injections of T3 (injected 
intraperitoneal) reduced dermal thickening and proliferation. The authors proposed that systemic administration 
might result in release of anti-proliferative factors from other cell sources, such as dermal fibroblast, or that 
compensatory activity of inactivating deiodinases would inhibit T3 action on keratinocytes. Analogous results 
were observed when studying the effect of TH during wound healing:  hypothyroid mice showed reduced 
proliferation and repair while administration of T3 promoted wound healing. However, analysis of positive 
regenerative markers, found up-regulated when T3 was administered, identified only negative TRE response 
elements, pointing out a more complex regulation and suggesting that T3 action might be indirect [82].  
The intestine, as the skin, is an epithelial tissue characterized by high turnover. The involvement of TH in intestine 
development as well as postnatal remodeling (maturation) has been extensively studied in mice and amphibians 
[83]. Interestingly, the intestine has been of particular interest during the last decades because of its structure, 
which offers an ideal model to study stem cell function [84] and cancer progression [85]. A mature intestine 
consists of a pluristratified epithelium organized in villus and intervillus spaces (Crypts); within the crypts a pool 
of resident stem cells slowly divide and give rise to proliferating progenitors that in turn differentiate while 
moving towards the villus. Signaling responsible for maintaining adult stem cells and driving their progeny 
maturation and differentiation have been studied in detail, and the Wnt/β-catenin pathway has emerged as one 
of the main regulators of this process. Recently, the work of Plateroti and coworkers has demonstrated that TH 
participate in this process, establishing an intimate crosstalk with the Wnt/β-catenin pathway (reviewed in [83]). 
Particularly, the authors highlighted the importance of liganded TH receptor α in supporting Wnt activation and 
promoting proliferation of the intestinal epithelium [50]; furthermore, they observed the direct interaction of TH 
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receptor α/β-catenin/TCF complex and the negative action of THRΔα (Which acts as a negative TH receptor as it 
has no ligand binding capacity).  
This positive effect of TH in promoting cell proliferation can be extended to others tissues such as liver, pancreas 
and kidneys [86]. With regards to the liver, the first observations that the thyroid function correlates with liver 
regeneration are dated back to the 1930s [87]; since then many laboratories have analyzed the relation between 
TH and liver regeneration [88-95]. From these studies, two main conclusions can be draw: physiological levels of 
TH are required for proper liver regeneration and T3 acts as a potent mitogen on liver hepatocytes. More 
recently, the work of Columbano and coworkers characterized the molecular mechanisms of these TH actions. 
They reported that T3 induces hepatocytes proliferation in a TH receptor β dependent mechanism [96], by 
promoting β-catenin stabilization and activity [97] with consequent activation of cyclin D (a known marker of 
hepatocytes proliferation). Aside from their participation in liver regeneration, TH regulate hepatocytes function 
and metabolism.  
Although the presented examples indicate a conserved positive regulation of cellular proliferation by TH, other 
organs modulate TH activity for other purposes. Skeletal muscle is an important target of TH activity, which 
regulate function, homeostasis and metabolism (recently reviewed in [98]). Vice versa, the skeletal muscle 
regulates peripheral TH conversion, thereby modulating TH systemic levels. Indeed, deiodinase type-II (DIO2) 
conversion within myoblasts accounts for roughly 40% of total T3 peripheral activation and their contribution 
increases in hypothyroid individuals. During postnatal development, the rise in TH levels promotes the 
maturation of muscle fibers and their increase in size (mainly hypertrophy). In particular, TH regulate via their 
TH receptors (mainly the α isoform) expression levels of MYOD1, the master regulator of myoblast 
differentiation. Hypothyroidism is associated with incomplete muscle differentiation and improper maturation 
of muscle fibers [99]. In addition to the regulation of skeletal muscle function and metabolism, recent findings 
pointed out the importance of TH during muscle regeneration. The muscle shows some regenerative capacities: 
repopulation of damaged fibers relies on the satellite cells, which are quiescent adult progenitors intercalated 
within the myoblast. Following loss of myofibers, satellite cells re-enter the cell cycle and proliferate; 
consequently proliferating progenitors exit the cell cycle and differentiate in novel myofibers. As observed in 
postnatal muscle maturation, TH activity promotes differentiation of satellite cells; characterization of muscle 
regeneration in satellite cells lacking deiodinase type-II or type-III (Induced by PAX8-CRE) activities pointed out a 
crucial role of deiodinases in regulating intracellular TH availability during this process. In particular, following 
damage satellite cells upregulate deiodinase type-III expression reducing intracellular TH activation, this 
hypothyroid state allows the cells to enter the cell cycle and amplify the progenitor pool [100]. Following a wave 
of cell divisions, proliferating progenitors downregulate deiodinase type-III and activate deiodinase type-II, 
switching from a hypothyroid to a hyperthyroid state; this in turn promotes MYOD1 expression and consequent 
differentiation of progenitor cells into mature myofibers [101].  
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In conclusion, TH participate in multiple homeostatic/regenerative processes establishing different networks in 
an organ and cell specific manner. Importantly, TH are able to either enhance or block proliferation according to 
the target tissue; thereby suggesting that this conserved system of “TH responsiveness” (TH related factors: 
receptors, deiodinases, transporters) transduces different signals based on the relative amounts of the partners 
it interacts with.  
 
2.1.6.3 Thyroid hormones and cancer  
 
Considering their pleiotropic actions observed in various tissues of the body, is not surprising that TH activity is 
also associated with cancer formation and progression (Recently reviewed in [102]). Indeed, many types of 
cancer show dysregulated TH signaling or driving mutations in TH related genes. However, it is important to 
mention that until now many divergent effects of TH have been described according to the tumor and the model 
of investigation.  
The first evidence that deregulation of TH signaling is involved in cancer formation came from the observation 
that the proto-oncogene c-ErbA other is not that a mutated TH receptor α [103]. TH receptor α plays an important 
role in intestinal development and homeostasis, by interacting with the Wnt signaling ([50] See previous 
paragraph). Kress and collaborators reported that overexpression of TH receptor α in intestinal cells is able to 
trigger hyper-proliferation of the intestinal epithelium and consequent adenoma formation; however the 
authors observed that over expression of TH receptor α per se is not able to induce cancer formation but acts as 
a tumor promoting factor when mutated APC is present [104]. The TH receptor isoform β is aberrantly expressed 
in different cancers, most often mutations lead to gene silencing or disruption of the TH binding capacities [105, 
106]. Multiple studies on cancer cell lines revealed that re-expression of wild-type receptor can antagonize 
oncogenic signaling such as Kras, Pi3k-Akt, or Wnt and reduce proliferation and survival of cancer cells [107, 108].  
This has been observed also in vivo, in a model of hepatocellular carcinoma (HCC), in which TH promote tumor 
regression while hypothyroidism favors tumor initiation [109]. Particularly, the authors observed that the 
beneficial effects of TH were abolished when TH receptor β was silenced. Later, the same group demonstrated 
the efficacy of a selective TH receptor β ligand (GC-01) to induce tumor regression as previously reported using 
T3; importantly the authors highlighted that GC-01 was not as efficient as T3, suggesting the putative 
involvement of TH receptor α isoform [110]. In contrast, results obtained in Insulinoma cells, demonstrated that 
TH receptor β acts as a pro-survival signal in these cells by mediating Akt activation in a T3-dependent fashion 
[111]. Furuya and coworkers analyzed the effect of a genetic mutation in the TH receptor β isoform observed in 
a patient with TH-resistance [112]. Particularly, they generated a mouse model carrying a mutated TH receptor 
β (named THRβ-PV), which has completely lost binding capacities to TH and therefore acts as a dominant-
negative of TH genomic action. THRβ-PV mice spontaneously developed follicular thyroid tumors characterized 
by constitutive activation of Akt, a feature also observed in humans. The authors demonstrated that mutated TH 
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receptor β was responsible for the over-activation of Akt; indeed, THRβ-PV has increased binding capacities to 
p85α and leads to aberrant activation of the Pi3k-Akt signaling cascade. Despite the involvement of TH receptors 
α and β, a great interest towards the role of the integrin αVβ3 receptor in tumorigenesis has recently rose. This 
is due in particular to the observation that integrin αVβ3 is highly expressed in dividing endothelial cells and 
many tumor cells. Recently reviewed in [113], the group of Davis propose that TH, through the integrin αVβ3, 
can act as promoters of proliferation and survival on different cancer cells; furthermore, they highlight the major 
contribution of T4, rather than T3, in modulating these actions.  
Deiodinase type-III is referred to as an oncofetal protein: its expression is often increased in solid tumors and is 
associated with high proliferation (reviewed in [114]).  An example of this concept can be found in the basal cell 
carcinoma skin tumor where TH treatment inhibits tumor progression and metastasis formation [115]. 
Furthermore, with regards to colorectal cancer, Dentice and collaborators demonstrated that Deiodinase type-
III is highly expressed in cancer stem cells, which are characterized by high activation of the Wnt/β-catenin 
signaling [116]. Particularly, the authors reported that β-catenin promotes upregulation of Deiodinase type-III, 
thereby preventing local increase of TH. The same group observed that T3 treatment can sensitize cancer stem 
cells to chemotherapeutics by counteracting the Wnt/β-catenin signaling and promoting a more differentiated 
phenotype [117]. Aside from the Wnt/β-catenin other signaling involved in cancer have been reported to 
promote DIO3 (Reviewed in [45]).    
Furthermore, TH metabolic actions have been shown to affect tumor cells growth and survival. Many cancer cells 
generate energy through aerobic glycolysis, this shift in metabolism has been ascribed as “the Warburg effect” 
and appears to confer transformed cells growth and survival advantages (Reviewed in [118]). TH, by stimulating 
mitochondria biogenesis and function (see TH and metabolism), can antagonize the Warburg effect in breast 
cancer cells, resulting in chemotherapeutic sensitization [119].  
The above-mentioned observations are only a few examples of the many evidences collected with regards to the 
actions of TH in cancer. As described in developmental and homeostatic processes it appears clear that TH affect 
tumor formation and progression in a context dependent manner, which possibly rely on the specific driving 
tumorigenic signaling.  
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2.2 The pancreas 
 
The pancreas is a multifunctional organ, which can be divided into two main compartments: the exocrine and 
the endocrine pancreas. The exocrine pancreas consists of acinar cells that produce digestive enzymes and the 
ductal tree, which brings these digestive enzymes to the duodenum and secretes bicarbonate that reduces 
stomach acidity. Acinar cells are protein “factories”, specialized in synthesis and secretion of digestive enzymes; 
they are characterized by a high number of mitochondria, an extensive endoplasmic reticulum, and electron 
dense vesicles filled with digestive enzymes, named Zymogens. Multiple neurohormonal regulators, named 
secretagogues, regulate synthesis and release of zymogens (i.e. Cholecystokinin, acetylcholine etc. [120]). On the 
other hand, the endocrine pancreas regulates glucose homeostasis, by releasing hormones in the circulation. The 
endocrine pancreas is composed of the islets of Langerhans, interspersed clusters of cells that produces key 
metabolic hormones such as Insulin, Glucagon and Somatostatin. (See representation in figure 7). 
 
 
Figure 7: Representation of the cytological architecture of the pancreas. Taken from [121]. 
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2.2.1 Pancreas development 
 
In the last two decades a great effort in elucidating the molecular signaling that drive pancreatic development 
has brought a considerable amount of knowledge on this process (recently reviewed in [122]). In mammals, the 
pancreas originates from two distinct primordial buds (ventral and dorsal) that harbor independently from the 
foregut endoderm (Embryonic day 9 - E9 – for the mouse / gestation week 3 - G3W – in the human). Both 
pancreatic buds are composed of multipotent progenitor cells (MPC) expressing the pancreatic and duodenal 
homeobox 1 (Pdx1); the ventral and dorsal pancreas eventually fuse in a single organ and elongate (E11.5-12.5 / 
G5.6W). These early stages of pancreas development, referred to as primary transition, involve multiple 
determinant factors released particularly by the adjacent cardiac mesoderm. The secondary transition starts 
with expansion of the pancreatic epithelium, followed by differentiation of the MPC into adult pancreatic cells 
and tissue remodeling (From E12.5 until birth / ~G8W). While many signaling that drive pancreatic lineage 
specification have been elucidated, still little is known about pancreatic morphogenesis [123]. Notch signaling is 
one of the first restrictors of MPC competence: it specifies acinar precursors (Notch negative) and bi-competent 
ductal-endocrine cells (Notch positive); a process referred to as Tip-trunk segregation. Subsequently, the 
“mutually-exclusive” Ptf1a/Nkx6 switcher (two important transcription factors for pancreatic lineage 
specification) further consolidates Notch bimodal discrimination: on-Notch promotes Nkx6 expression, which in 
turn block Ptf1a, promoting an endocrine or duct fate; conversely off-Notch increases Ptf1a expression and 
represses Nkx6 [124]. A schematic representation of pancreatic lineage signaling is presented in figure 8.  
Together with the differentiation of pancreatic progenitor cells, their proliferation ensures that the pancreas 
reaches the proper mass at birth. Most of our knowledge on the signaling involved comes from animals models 
with selected genetic alterations.  The first signal known to promote proliferation of pancreatic progenitor cells 
is FGF (Fgf10), released from the adjacent mesenchyme [125]. More so, Wnt/β-catenin [126], Notch and Indian 
hedgehog (IHH) [122] among others have been described to be essential for pancreatic growth. It is worth 
mentioning that precise timing of regulation is crucial for proper pancreatic development: an example of this 
concept is well described by the work of Heiser and colleagues [127]. The authors characterized the effect of 
constitutive β-catenin activation (canonical Wnt effector) using two PDX1-driven recombinase Cre systems 
(named CREearly and CRElate) differing for about one day of expression (E10.5 vs E11.5). Comparison of the two 
mouse strains revealed that early activation of β-catenin induces pancreatic hypoplasia and prevents 
differentiation of MPC while the late induction results in normal differentiation and increased pancreatic growth. 
Overall an intricate network of signaling orchestrate pancreatic development in a spatial and time dependent 
fashion; as will be discussed in later sections the same key factors are often reactivated following pancreatic 
injury and participate in the regeneration of this organ. 
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Figure 8: Schematic representation of the key factors involved in pancreatic lineage specification. Taken from 
[128]. 
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2.2.2 Pancreatic diseases 
 
Although the most studied pancreatic diseases involve the endocrine pancreas (i.e. diabetes), the exocrine 
compartment also suffers many illnesses. Pancreatic exocrine inflammatory injuries, referred to as pancreatitis, 
can be divided into acute and chronic based on the time of persistence of the injury. Acute pancreatitis is the 
leading cause of hospitalization amongst gastrointestinal disorders in the United States; its severity varies from 
mild cases that spontaneously resolve themselves to severe pancreatitis, which leads to systemic inflammation 
and often mortality due to multiorgan dysfunction [129]. Chronic pancreatitis on the other hand, is characterized 
by the persistence of damage and inflammation within the pancreas for a long period, which often leads to acinar 
cell atrophy and, as previously mentioned, to pre-cancerous lesion formation [130]. Furthermore, chronic 
pancreatitis leads to a high fibrotic response by proliferation of resident pancreatic mesenchymal cells, often 
referred to as pancreatic stellate cells (PSC) [131]. Many risk factors have been associated with the incidence of 
acute and chronic pancreatitis: among them gallstones formation with physical obstruction of the common 
pancreatic-bile duct, smoking, and alcohol consumption. Most of our knowledge on the initiation and the 
progression of the disease comes from animal studies. The initiating event in pancreatitis is the premature 
activation of digestive enzymes within the pancreatic tissue and consequent self-digestion of the organ [132]. 
This process can be mimicked in the mouse by administrating supra-physiological doses of cerulein, an analog of 
cholecystokinin (CCK), which recapitulates this aberrant release and activation of digestive enzymes [132]. 
Following cerulein treatment inducing the initial cell damage, injured acinar cells release several cytokines that 
attract inflammatory cells within the pancreas. Concomitantly with inflammation, the pancreas triggers a 
regenerative response by which differentiated acinar cells re-enter the cell cycle and start to proliferate [133]. 
Moreover, injured acinar cells can transiently dedifferentiate; in this instance, acinar cells lose their zymogens 
content and acquire a ductal phenotype by re-expressing progenitor markers, a process known as acinar-to-
ductal metaplasia (ADM) ([134, 135]). ADM typically resolves itself over time; however, persistent (chronic) 
pancreatitis can lead to sustained ADM formation and subsequently to pre-cancerous lesions. 
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2.2.3 Pancreatic exocrine regeneration 
 
Tissue regeneration follows different mechanisms accordingly to the organ and the severity of injury 
investigated. While, for example, muscle and intestine show resident stem cells [136] able to repopulate the 
tissue following damage, the liver regenerates mainly through proliferation of differentiated hepatocytes [137]. 
Several studies have tried to identify resident stem cells in the adult pancreas; however, the lack of specific 
markers together with the plasticity observed by differentiated cells during injury have led to inconclusive results. 
One of the most “speculated” putative stem cell population are the centroacinar cells (CAC), which in Zebrafish 
have been demonstrated to serve as progenitors for both endocrine and exocrine cells [138-140]. Although a 
precise characterization of CAC progenitor properties in mammals is still missing, Furuyama and coworkers 
observed that Sox9+ duct cells (included CAC) sustain pancreatic tissue homeostasis and are able to differentiate 
in acinar cells [141, 142]. However, using a similar lineage tracing system, Kopp reported that Sox9+ cells act as 
progenitors only during embryogenesis and do not participate in adult tissue homeostasis or regeneration [143]. 
Recently two different studies, using lineage-tracing labeling of acinar cells, demonstrated the existence of high 
heterogeneity within the acinar compartment. Wollny et al. [144] used a low-labelling multicolor approach to 
track proliferation of small cluster of acinar cells over time; their analysis identified a subpopulation of 
proliferating acinar cells (Stmn1+) which appear to sustain alone the homeostatic tissue turnover. Furthermore, 
they demonstrated that upon injury non-proliferating acinar cells (Stmn1-) are able to express Stmn1 and 
proliferate to compensate for tissue loss. Westphalen and colleagues [145], on the other hand, identified a 
subpopulation of quiescent acinar cells (Dclk1+) which acts as facultative progenitor and demonstrated that 
Dclk1+ cells are required for pancreatic regeneration following pancreatitis (progenitor hypothesis). Whether 
these two subpopulations overlap has not yet been investigated, however both studies highlight that exocrine 
regeneration does not depend on resident stem cells. It is important to mention that exceptions to this 
observation have been described in models of severe acinar cells injuries (acinar cell ablation); in this scenario in 
fact, ductal cells can serve as progenitors and are able to repopulate the acinar compartment [146], a feature 
observed also in liver regeneration [147]. Although the contribution of other cell types to exocrine regeneration 
is still under debate, proliferation of differentiated acinar cells appears to sustain most pancreatic recovery. 
During the last decades, a great understanding of the signaling required for proper exocrine regeneration has 
been generated, among others the IGF-I [148], Wnt/β-catenin [149], HDAC [150] and TGF-β [151] have been 
demonstrated to regulate acinar cell proliferation during exocrine regeneration.  
Interestingly, comparing regenerative and developmental signaling shows a high degree of similarities. Examples 
of this include the re-expression of PDX1 within the acinar compartment following pancreatitis, the increased 
Notch expression in transiently de-differentiated acinar cells (ADM), or the Wnt-β-catenin pathway, already 
described in pancreatic development. As an example, starting from the pancreatic secondary transition (~E12.5) 
β-catenin (canonical-Wnt signaling) is required for proper expansion of committed acinar cells; Keefe and 
coworkers investigated if this requirement is retained during postnatal life and pancreatic regeneration. They 
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observed that β-catenin in indispensable for postnatal growth of acinar cells, furthermore induction of 
pancreatitis to mice harboring pancreas specific deletion of β-catenin resulted in a marked decrease in acinar cell 
proliferation, while no differences in the level of pancreatic damage or inflammation were observed [149].  
In conclusion, much of the signaling that drive pancreatic organogenesis reawake during tissue regeneration 
[152]; importantly, many of those pathways do not necessary resemble their developmental function and may 
triggers different signals.  Interestingly, a similar reawakening of developmental signaling has been observed also 
with regards to the development of pancreatic cancer (recently reviewed in [153]). 
 
2.3 Thyroid hormones and Pancreas 
 
TH affect both the development as well as the adult stage of the pancreas. Much of our knowledge about the 
action of TH during pancreas development comes from studies of amphibian metamorphosis. Amphibian 
pancreas development shares many similarities with mammalian’s one but differs particularly on the 
morphogenesis of the adult pancreas.  The anuran (tadpole) pancreas consist of a “spongy” tissue which lacks 
any ductal system; at the onset of metamorphosis the pancreas undergoes dramatic changes that involve mainly 
cell dedifferentiation and apoptosis (also referred as “partial degeneration followed by regeneration” – Janes, 
1937 [154]). This process is entirely TH dependent, in fact TH appear to be essential to inducing the 
dedifferentiation of pancreatic cells but seems disposable for the re-differentiation phase [155, 156]. Similarly to 
the amphibian counterpart, mouse pancreatic explants (E12.5) treated with T3 show acinar dedifferentiation and 
increased expression of ductal marker Sox9 [157], a process also observed in adult primary acinar cells when TH 
receptor α (THRα) is overexpressed and T3 added to the culture media [158]. Interestingly, the authors [157] 
demonstrated the pancreatic expression of TH receptor α as early as E12.5, which coincides with the beginning 
of the secondary transition when cell lineage specification begins. It is worth mentioning that this developmental 
stage corresponds to the earliest detection of maternal TH within the embryo of both rodents and human [61] 
as well as the earliest activation of TH signaling documented during murine embryogenesis [60]. A possible 
mechanism for this TH dependent dedifferentiation of acinar cells may involve the Notch signaling, which in 
Xenopus l. is directly activated by TH [159]. In fact, forced activation of Notch during pancreas development 
promotes the differentiation of pancreatic progenitors towards a ductal phenotype at the expenses of acinar and 
endocrine lineages, similar to that reported for TH [160, 161].  Studies in later stages of development or postnatal 
life highlighted different functions of TH in pancreas organogenesis. Harris and colleagues for example, reported 
that perinatal hypothyroidism increases β-cell proliferation and insulin production during sheep development, 
without affecting pancreatic size [162]. This is in strike contrast to what was observed in the rat, in which T3 
appears to promote β-cell maturation and increases pancreatic growth, mainly due to increased number of acinar 
cells, during early post-natal life [163, 164]. These discrepancies observed with regards to TH actions on the 
pancreas may be explained by interspecies differences, or by changes in the responsiveness properties of 
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pancreatic cells during development, which involve differential expression of TH receptors as well as deiodinases 
enzymes. Analyses of TH receptors expression within the developing pancreas revealed a shift from almost only 
TH receptor α expression, at early stages (E12.5) to relative prevalence of the TH receptor β isoform at birth 
[157], these changes correlate with a different cellular localization of TH receptor isoforms α and β in early 
postnatal life [164]. In support of this hypothesis, analysis of the effect of T3 supplementation in adult pancreas 
revealed no induction of acinar cell dedifferentiation, as observed during development; on the contrary, several 
studies highlighted that TH promote acinar cell proliferation in a TH receptor β dependent mechanism [86, 96, 
165]. Overall, multiple evidences of an intimate relationship between TH and pancreatic development and 
function exist, however further analyses on the expression and distribution of TH receptors, deiodinases as well 
as the integrin αVβ3, are required to better clarify the role of TH within the pancreas. 
 
3. Aim of the project 
 
Following acute pancreatitis, pancreatic acinar cells are able to re-enter the cell cycle and start to proliferate. 
However, pancreatic regenerative capacities are limited, and persistence of damage often leads to pancreatic 
insufficiency. Although many of the signaling that drive acinar cell proliferation have been characterized in the 
last two decades, little is known about the initiating events that trigger this process. Based on the observations 
that TH participate in pancreas development and act as mitogens on adult pancreatic acinar cells, their putative 
involvement in pancreatic regeneration seems plausible. In the present project, we sought to characterize the 
involvement of TH during pancreatic acinar cell regeneration and the molecular mechanisms of T3-driven acinar 
cell proliferation.  
In particular, the following questions were addressed: 
-Are TH locally regulated in response to acute pancreatitis? 
To investigate whether TH are locally regulated following pancreatic damage we used the well established model 
of serial cerulein injections to induce pancreatitis and characterized levels of TH within the pancreas as well as in 
the blood during the progression of the disease. Furthermore, to investigate intracellular regulation and activity 
of TH we quantified expression levels of deiodinases and TH receptors genes in the pancreas and isolated acinar 
cells.  
-What is the effect of acinar specific conditional KO of DIO3? 
Mice with an acinar cell specific conditional KO for DIO3 were generated by crossing DIO3fl/fl and ELA-CreERT2Tg/+ 
strains. To investigate the putative effect of DIO3 deletion on pancreatic homeostasis we characterize pancreatic 
specimens harvested from healthy mice immediately after induction of recombination via tamoxifen treatment 
as well as one month post-tamoxifen. Next, we compared the response to cerulein induced acute pancreatitis 
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between transgenic and control mice.  Based on the reported observations that TH promote acinar cell 
proliferation, we focused on the characterization of acinar cell regeneration; for this reason, level of acinar cell 
proliferation was determined by immunohistochemistry (IHC) as well as gene expression of cell cycle regulators 
(i.e. cyclins). Furthermore, we investigated if acinar cell deletion of DIO3 alters the degree of damage and 
inflammation; to this aim, we measured Amylase and Lipase levels in the serum, two common markers of acinar 
damage, and quantified infiltrating cells within the pancreas. 
-Is pancreatic regeneration altered during thyrotoxicosis or hypothyroidism? 
We questioned the effect of systemic alterations of TH during pancreatic regeneration: thyrotoxicosis was 
induced by T3 injections whereas hypothyroidism by supplementation of sodium perchlorate and methimazole 
by drinking water. As mentioned above, we focused our analysis on the regenerative potential of acinar cells and 
characterized levels of damage and inflammation at the onset and during the progression of the disease. 
-What are the molecular mechanisms of T3 driven acinar cell proliferation? 
Analyses of the questions reported above brought us important results on the function of TH in pancreatic 
regeneration; for these reasons, we decided to extend our study and investigate the molecular mechanisms of 
T3-driven acinar cell proliferation. To this aim, we injected T3 to healthy mice in order to avoid the presence of 
damage and inflammation. We tested dose and time dependence of T3 induction of proliferation; furthermore, 
we determined the activation of selected signaling candidates, described in the literature to modulate acinar cell 
proliferation in vivo. Finally, we tested the putative involvement of HDAC, Akt, and TGF-β pathways; to this aim, 
we blocked each of these targets by either pharmacological inhibition or genetically modified mouse models. 
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Abstract 
Regeneration of the exocrine pancreas is a critical process in the pathophysiology of pancreatic diseases, as limited 
or defective regeneration is associated with organ dysfunction and patient morbidity. In this context, elucidating 
the signalling pathways that trigger and sustain pancreatic regeneration is pivotal to develop therapeutic 
interventions promoting the regenerative process. 
In this study, we discovered that levels of thyroid hormones and deiodinases enzymes, which modify the biological 
activity of thyroid hormones, increased in the pancreas upon induction of acute pancreatitis. This transient increase 
of regional thyroid hormone availability was required to promote proliferation of pancreatic acinar cells, and 
consequent pancreatic regeneration. By using genetic approaches to locally increase the levels of the biologically 
active thyroid hormone 3,3’,5-triodo-L-thyronine (T3)  in the pancreas, we could show that endogenous T3 acts 
as mitogens for acinar cells without affecting the extent of tissue damage or the development of inflammatory 
infiltration. Moreover, by manipulating pharmacologically the systemic levels of thyroid hormones, we 
demonstrated not only that decreased levels of circulating thyroid hormones impair acinar proliferation but also 
that exogenous administration of T3 is effective in boosting acinar cell proliferation upon induction of pancreatitis. 
In search of the molecular mechanisms underlying the observed phenotype, we showed that the mitogenic effect 
of T3 on acinar cells is the result of a tightly controlled and concerted action of different signaling pathways, 
including histone deacetylase, Akt, and TGF signaling, which regulated acinar proliferation in a positive and 
negative manner. 
In conclusion, our data suggest that local availability of thyroid hormones in the pancreas is required to promote 
acinar cell proliferation.  In addition, we propose that thyroid hormone signaling could be exploited to develop 
therapeutic regimens aiming at enhancing pancreatic regeneration. 
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Introduction 
Acute pancreatitis, a debilitating inflammatory 
disease of the pancreas, is a major cause of 
gastrointestinal hospital admission [1]. The injury of 
the organ consequent the development of the disease 
leads to dysfunction and, in its severe forms, necrosis 
of exocrine pancreatic tissue, resulting in high 
morbidity and mortality. In this context, boosting 
regeneration of the injured pancreas is a key 
therapeutic target to restore the activity of the organ 
and limit the pathological implications associated 
with impaired pancreatic function.  
In this work, we aimed to identify molecular factors 
that act as mitogens for pancreatic acinar cells and 
thus have the potential to be exploited therapeutically 
to promote pancreatic regeneration. Pancreatic acinar 
cells are ideal candidates to sustain the recovery of 
the organ following inflammatory insult, as not only 
constitute the vast majority of the exocrine pancreatic 
tissue, but also harbor the potential to proliferate in 
their adult state. Indeed, fully differentiated acinar 
cells, committed to the synthesis of digestive 
enzymes, are able to transiently de-differentiate to a 
progenitor-like state and re-enter a cell cycle program 
in response to pancreatitis [2]. However, this 
proliferative ability, reported in humans and animal 
models, is often limited, thus hampering the 
regeneration capacity of the pancreas. In recent years 
multiple signaling pathways and transcription factors 
have been described to regulate acinar cell 
proliferation following pancreatitis (reviewed in [3]). 
These studies revealed a complex network of signals 
that sustain cell de-differentiation or promote re-
differentiation of acinar cells after injury.  
Importantly, these works highlight the concept that 
the molecular factors that drive the process of 
regeneration in the adult pancreas are also implicated 
in the developmental program of the organ. However, 
our knowledge regarding molecules that trigger or 
sustain proliferation of acinar cells is still limited. In 
this study, we investigated whether a proliferative 
stimulus to promote acinar cell proliferation is 
provided by a local increase of thyroid hormone 
levels in the pancreas upon induction of pancreatitis. 
The hypothesis of local hyperthyroidism to support 
pancreatic regeneration was built on independent 
lines of evidences. Firstly, consistent with the fact 
that a developmental program is re-activated during 
pancreatic regeneration, thyroid hormones play a 
functional role in the development of pancreatic cells 
during organogenesis, demonstrated in both 
amphibian and mammalian pancreas (reviewed in 
[4]). Secondly, adult acinar cells harbor the molecular 
machinery to respond to thyroid hormones and start 
proliferating when triiodothyronine (T3), the 
biologically active thyroid hormone that binds to 
thyroid hormone receptors [5], is administered 
exogenously [6, 7]. In this context, previous studies 
using a selective receptor agonist identified TR as 
the critical isoform of thyroid hormone receptor that 
promotes  proliferation of pancreatic acinar cells upon 
T3 administration [8]. Finally, thyroid hormones act 
as mitogens during regeneration of liver [9], an organ 
that shares the same embryological lineage with the 
pancreas. 
To test our hypothesis that thyroid hormones are 
endogenous mitogens for pancreatic acinar cells 
during pancreatitis, we utilized genetic and 
pharmacological approaches to alter local and 
systemic levels of thyroid hormones, and assessed 
acinar proliferation following cerulein-induced 
pancreatitis, the most widespread experimental 
method to generate the disease in rodents [3]. 
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Materials and methods 
Animal experiments 
All animal experiments were conducted in 
accordance with Swiss federal animal regulations and 
approved by the cantonal veterinary office of Zurich. 
All studies involving animals are reported in 
accordance with the ARRIVE guidelines for 
reporting experiments involving animals. Mice used 
in this study were adult 8–14 week old male C57BL/6 
mice (Envigo, Itingen, Switzerland), conditional 
TGFβ receptor II deficient mice (TGF-RII KO) [10] 
bred in our facility, and mice with inducible ablation 
of Deiodinase 3 in acinar cells (ELACreERT2/D3flox/flox, 
D3KO) bred in our facility. D3KO animals were 
generated by crossing mice harboring elastase (ELA) 
promoter driven Cre transgene ELACreERT2Tg/+ [11] 
with  transgenic mice expressing Deiodinase 3 (D3) 
flox/flox  [12]. Tamoxifen (TAM -SPEC)-driven 
recombination was induced with 100 µL injection of 
20 mg/mL tamoxifen (Sigma-Aldrich) daily for 5 
consecutive days as described [13]. The CRE-
negative littermates were used as controls.  
Acute pancreatitis was induced via six intraperitoneal 
(i.p.) injections of 50 µg/kg cerulein, administered 
hourly on two consecutive days. Control animals 
received 0.9% NaCl injections. Hyperthyroidism was 
induced with daily injections of 400g/Kg T3. 
Control animals received vehicle 0.1M NaOH, pH 7.4 
with 0.5%BSA injections. 
Hypothyroidism was induced by supplementation of 
1% NaClO4 and 0.1% methimazole (MMI) by 
drinking water for 28 days [14]. 
Class I HDAC inhibitor MS-275 (Selleckchem, 
Houston, USA) was injected daily i.p. at 20 mg/kg, 
starting one day before the first T3 injection (See 
scheme Fig.S4). 
Akt inhibitor, MK-2206 (A3010, APExBIO) was 
injected four times daily i.p. at 8 mg/kg, starting 
before the first T3 injection (see scheme Fig.S5). 
Mice were anesthetized by isoflurane inhalation. The 
harvest times for the different experiments are 
expressed as hours after the first cerulein or T3 
injection and are specified in the individual figure 
panels. 
Groups of 5 animals were tested for each 
experimental condition. Animals were assigned 
randomly to different experimental groups for all in 
vivo studies. Data collection and evaluation of all 
experiments were performed blinded to the group 
identity.  
Primary acini were isolated from C57BL/6 mice 24h 
after induction of pancreatitis via collagenase 
digestion according to [15]. 
Immunohistochemistry 
Pancreas specimens were embedded in paraffin for 
histological analyses as described [16]. Primary 
antibodies used in this study were: rabbit anti-Ki67 
(#ab16667, Abcam, Cambridge, UK, 1:200); rabbit 
anti-phospho-H3(06-570, Millipore) rabbit anti-
amylase (#A8273-1VL, Sigma-Aldrich, Buchs, 
Switzerland, 1:1000); rabbit anti-PU.1 (#2266, Cell 
Signaling Technologies, Danvers, MA, 1:200); rabbit 
anti-phospho-histone H2A.X (Ser139) (#9718, Cell 
Signaling Technologies, Danvers, MA, 1:500); rabbit 
anti-cleaved Caspase-3 (Asp175) (#9661, Cell 
Signaling Technologies, Danvers, MA, 1:1500). 
Secondary antibodies used in this study were 
biotinylated goat anti-rabbit IgG (H + L), included in 
the Vectastain® ABC Kit (PK-4001, Vector 
Laboratories, Peterborough, UK). All staining, with 
the exception of Amylase, were performed with a 
DAKO autostainer Link 48. 
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Quantification of labelled cells was performed in at 
least 10 randomly selected high-power fields (×200) 
per slide using the NIS Elements BR Analysis and 
Cell^P analysis software.  Number of positive cells 
was normalized on the area occupied by pancreatic 
acinar cells present in each power field. Pancreatic 
ducts, islets and vessels were excluded from the 
analysis. 
Quantitative analysis of ADM was performed as 
described in [17]. Briefly, paraffin-embedded 
pancreas specimens were immunostained for 
amylase, slides were scanned with a NDP 
NanoZoomer Digital Pathology Slide Scanner 
(Hamamatsu) and analyzed for ADM lesions in a 
blinded fashion. ADM present in the entire pancreas 
slide of 5 mice from each treatment condition were 
quantified by manual counting. ADM were identified 
according to: i) loss of amylase content, ii) structural 
re-organization into tubular complexes, iii) stromal 
reaction characterized by presence of cell infiltrates. 
The area occupied by ADM was expressed as 
percentage of total pancreatic area present in each 
slide. 
Biochemical analyses 
Levels of enzymatic activity of amylase and lipase 
were measured in blood serum collected via heart 
puncture. Enzyme activities were measured using the 
Fuji Dri-Chem 4000i analyzer (FUJIFILM 
Corporation, Tokyo, Japan).  
Blood levels of F-T4 and F-T3 were quantified with 
analyzer Cobas 8000 Modul-System e 602 (Roche), 
according to the manufacturer instruction. 
Tissue levels of F-T3 were measured using an Elisa 
Kit (CUSABIO Technology LLC, Houston, TX, 
USA) according to the manufacturer instruction. 
 
Nuclear protein extraction and HDAC activity 
Nuclear proteins were extracted from 20 mg of 
pancreatic tissue with the EpiQuik™ Nuclear 
Extraction Kit (Epigentek Group Inc, Mountain 
View, CA) and HDAC activity was measured in the 
nuclear extracts with the fluorimetric EpiQuik HDAC 
Activity/Inhibition Assay Kit (Epigentek Group Inc. 
Mountain View, CA), following the manufacturer's 
instructions.  
Western blotting 
20 mg of pancreatic tissue was homogenized in RIPA 
buffer containing a protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). Protein 
concentrations were determined by a Bradford 
protein assay (BioRad, Hercules, CA, USA). 20 g of 
proteins were resolved by SDS-PAGE 
electrophoresis and blotted onto nitrocellulose 
membranes using a V3 Western Workflow system 
(BioRAd, Hercules, CA, USA) according to the 
manufacturer's protocols.  
Membranes were incubated with primary antibodies 
overnight at 4°C. Primary antibodies used in this 
study were: p-AKT (4051, Cell Signaling), AKT 
(9272, Cell Signaling); rabbit anti -tubulin (2125, 
Cell Signaling); p-Smad2/3 (Ser423/425) (8828, Cell 
Signaling); SMAD2/3 (8685, Cell Signaling). 
Transcript analysis  
Total RNA was extracted from pancreatic tissue, as 
described previously [18], and RNA quality control 
was performed by RIN (RNA Integrity Number) 
measurement using a 2100 Bioanalyzer system 
(Agilent, Santa Clara, CA, USA). RNA was reverse-
transcribed with qScript™ cDNA SuperMix (Quanta 
Biosciences, Beverly, CA, USA). Gene expression 
was measured by real-time PCR on a 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, 
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USA) using Taqman probes (Applied Biosystems, 
Foster City, CA, USA). Transcript levels were 
normalized using 18S RNA as a reference and 
expressed as 2-ΔΔCt relative to the value of control 
animals. 
Statistics  
Groups of 5 animals were tested for each 
experimental group. The data are expressed as means 
± SEM. The statistical significance of differences in 
the means of experimental groups was determined 
using an unpaired, two-tailed Student's t test or one-
way analysis of variance followed by Dunnett post 
test (GraphPad Prism 7; GraphPad Software, Inc.) 
and a probability value <0.05 was considered 
statistically significant. 
 
Results  
Local hyperthyroidism is induced in the pancreas 
during acute pancreatitis 
To test whether thyroid hormones act as mitogens 
during pancreatic regeneration upon inflammatory 
injury, we first investigated whether T3 levels 
increase in the pancreas following induction of acute 
pancreatitis with serial injections of cerulein. 
Cerulein administration (scheme depicted in Fig.1A) 
results in a time-dependent increase in acinar cell 
proliferation, as quantified by the levels of acinar 
cells positive for the general proliferation marker 
Ki67 (Fig.1B). Interestingly, we observed a transient 
surge of free T3 (F-T3) levels, the biologically active 
form of the hormone (reviewed in [5]), in the 
pancreas (Fig.1C), the kinetic of which preceded the 
peak of acinar cell proliferation. Conversely, levels of 
thyroid hormones F-T4 and F-T3 transiently 
decreased in blood (Fig.1D). Increased F-T3 levels in 
pancreatic tissue may derive from increased  uptake 
from the circulation of either T3 and/or of T4, with  
subsequent conversion into T3 by the action of 
deiodinases (DIO) enzymes, which regulate the 
intracellular hormone concentration in a time- and 
tissue-specific fashion, independently on the levels 
present in blood [5]. We detected an early up-
regulation of DIO2, the enzyme responsible for local 
T4 to T3 conversion in target cells [19], in the 
pancreas in response to induction of pancreatitis 
(Fig.1E). Importantly, DIO3, responsible for 
inactivating both T4 and T3 hormones, was also up-
regulated in the pancreas, while DIO1 expression was 
transiently down-regulated. DIO2 and DIO3 up-
regulation was also detected in pancreatic acinar cells 
isolated after 24h of cerulein treatment (Fig.1F), 
suggesting that acinar cells are able to regulate the 
intracellular concentration of thyroid hormones. 
Analyses of DIO expression in multiple organs 
revealed that DIO regulation was either detected 
exclusively (DIO1, 2) or showing the highest 
regulation (DIO3) in the injured pancreas (Fig.1G).  
Collectively, these data support the hypothesis that 
increased levels of F-T3 and consequent local 
hyperthyroidism are specifically and transiently 
induced in the organ in response to acute pancreatitis.  
Genetic ablation of DIO3 in acinar cells increases 
acinar proliferation during acute pancreatitis  
To test whether the transient hyperthyroidism 
observed upon induction of pancreatitis promotes 
acinar proliferation, we increased the levels of thyroid 
hormones in acinar cells by knocking out DIO3 in 
these cells using a tamoxifen-inducible approach 
(scheme depicted in Fig.2A).  In the absence of 
pancreatitis, DIO3 conditional KO (D3KO) mice 
presented a normal phenotype indistinguishable from 
control mice. This was evident by normal pancreatic 
histology (Fig.2B), lack of acinar damage (Fig.S1A), 
or development of inflammation (Fig.2C). Similarly, 
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no differences in basal levels of acinar cell 
proliferation were observed between transgenic and 
control mice (Fig.2D), even one month after 
tamoxifen treatment (Fig.S1B), suggesting that 
ablation of DIO3 does not compromise pancreatic 
homeostasis in untreated mice. Similarly, levels of 
pancreatic and circulating thyroid hormones were not 
altered in D3KO mice in untreated conditions 
(Fig.2E). However, upon induction of acute 
pancreatitis (treatment scheme depicted in Fig.2F), 
proliferation of acinar cells was higher in D3KO 
animals, as determined by number of Ki67 positive 
cells ( Fig. 2G) and cyclin expression in the pancreas 
(Fig.2H). Increased acinar proliferation in D3KO 
animals was preceded by increased levels of free-T3 
in the pancreas (Fig. 2I). Moreover, increased acinar 
proliferation was not a consequence of increased 
pancreatic injury upon induction of pancreatitis, as 
blood levels of amylase and lipase, the most reliable 
indicators of acinar cell damage, were comparable in 
control and D3KO mice (Fig.2J). Similarly, it was 
not driven by increased recruitment of PU.1-positive 
inflammatory cells, as their number was comparable 
in the two strains (Fig.2K). Finally, increased acinar 
proliferation was not accompanied by changes in the 
levels of acinar-to-ductal metaplasia (Fig.2L), a 
transient de-differentiation of acinar cells observed in 
the tissue during pancreatic regeneration. 
Collectively, these data indicate that ablation of DIO3 
in acinar cells is sufficient to increase pancreatic 
levels of F-T3 and enhance acinar proliferation upon 
induction of acute pancreatitis.   
Systemic alterations of thyroid hormone levels 
modulate acinar cell proliferation during acute 
pancreatitis 
After showing that local hyperthyroidism induced in 
the pancreas following acute pancreatitis supports 
acinar proliferation, we then investigated whether 
systemic alteration of thyroid hormone levels affect 
the extent of acinar proliferation during the disease. 
Systemic hyperthyroidism was induced by daily 
administration of T3 starting after the first set of 
cerulein injections, while systemic hypothyroidism 
was induced by administration of NaClO4 and 
methimazole (MMI) for 28 days (regimen scheme 
depicted in Fig.3A). Analysis of thyroid hormone 
levels in serum confirmed the efficacy of the 
treatments as T3 administration increased F-T3 levels 
and decreased F-T4, as a consequence of negative 
feedback loop, while MMI administration decreased 
the levels of both hormones (Fig.3B).  
T3 treatment significantly increased proliferation of 
acinar cells (Fig.3C), and cyclin expression in the 
pancreas (Fig.3D). Conversely, MMI administration 
decreased both acinar proliferation and cyclin 
expression (Fig.3C, D). Administration of T3 to 
hypothyroid mice rescued the defective acinar 
proliferation (Fig.3E), further demonstrating that 
increased levels of this hormone are sufficient to 
boost acinar cell proliferation. 
Changes in acinar proliferation observed during 
systemic hyper- and hypothyroidism were not a 
consequence of changes in initial damage of acinar 
cells or infiltration of inflammatory cells. Indeed, 
manipulation of thyroid hormone levels did not 
modify serum levels of amylase and lipase, early 
indicators of acinar cell damage (Fig.3F).  Similarly, 
levels of inflammatory cell infiltration, quantified by 
the number of PU.1-positive cells, were unchanged 
by induction of hyper- or hypothyroidism (Fig.3G). 
Furthermore, differences in acinar replication were 
not correlated to differences in acinar apoptosis or 
DNA damage, as shown by quantification of cleaved-
caspase3 (Fig.S2A) and p-H2A.X (Fig.S2B). 
Collectively, these data suggest that altering the 
systemic levels of thyroid hormones does not modify 
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pancreatic sensitivity to cerulein administration and 
recruitment of inflammatory cells. In addition, they 
indicate that changes in acinar proliferation induced 
by systemic variation of thyroid hormone levels are 
independent from the levels of acinar cell injury and 
inflammatory cell infiltration. 
Finally, to demonstrate that T3 sustains acinar cell 
proliferation independently from T4, we administered 
Iopanoic acid (IOP), a specific deiodinase inhibitor 
that blocks T4 to T3 conversion [20], in combination 
with cerulein (Fig.3H). Analysis of thyroid hormone 
levels confirmed that IOP administration decreased 
blood levels of F-T3, whereas F-T4 amount was 
unchanged (Fig.3I). Similar to what we observed in 
hypothyroid mice, IOP-treated animals showed a 
significant decrease in the number of proliferating 
acinar cells (Fig.3J). Overall, these data demonstrate 
the existence of a positive correlation between thyroid 
hormone levels, in particular T3 availability, and 
proliferation of acinar cells in response to acute 
pancreatitis.  
Acinar proliferation induced by T3 
administration is promoted by HDAC activity and 
Akt signaling  
Next, we investigated the molecular mechanisms 
underlying the mitogenic action of T3 in pancreatic 
acinar cells. To be able to focus exclusively on T3 
action without the confounding aspect of pancreatic 
inflammation, we supplemented T3 in vivo in the 
absence of cerulein-induced pancreatitis (scheme 
depicted in Fig.4A). Analysis of acinar cells positive 
for proliferation markers Ki67 and pH3 (Fig.4B) and 
pancreatic expression of early and late cyclins 
(Fig.S3A) showed that T3 exerted a profound 
mitogenic effect on acinar cells 96 hours after the 
beginning of the treatment, as previously described 
[6]. Moreover, T3-mediated induction of acinar 
proliferation was dose-dependent (Fig.4C) and it did 
not elicit inflammatory cell infiltration (Fig.4D) or 
morphological alteration of pancreatic tissue 
(Fig.S3B), which further support our observation that 
T3 does not influence pancreatic inflammation during 
the development of pancreatitis.  
T3 is known to regulate multiple pathways within the 
cells by genomic and non-genomic actions [21]. Here 
we tested whether signaling pathways that are known 
to support acinar proliferation during pancreatitis are 
activated in the pancreas upon T3 administration in 
the absence of inflammation. We first assessed 
whether T3 administration triggered the upregulation 
of histone deacetylases (HDAC), a class of epigenetic 
modifiers that was recently shown to be activated 
during pancreatitis and promotes proliferation of 
acinar cells [22, 23]. T3 treatment was sufficient to 
increase both the expression of different HDAC 
isoforms (Fig.4E) and total HDAC activity in the 
pancreas (Fig.4F). In vivo treatment with the specific 
class I HDAC inhibitor MS-275 (treatment scheme 
depicted in Fig.S4A) effectively reduced HDAC 
activation (Fig.S4B) and reduced acinar cell 
proliferation (Fig.4G) and cyclin B expression 
(Fig.S4C) induced by T3. Inhibition of acinar cell 
proliferation was accompanied by increased 
expression of cell cycle inhibitors p15/INK4B, 
p16/INK4A, and p18/INK4C (Fig.S4D). 
We then investigated whether T3 administration 
promoted the activation of phosphatidylinositol 3-
kinase (PI3K)/Akt. The Akt pathway is important for 
pancreatic proliferation, as reduction of this signaling 
suppresses acinar cell division [24] and its 
constitutive activation in adult acinar cells leads to 
excessive proliferation and malignant transformation 
[25]. T3 supplementation significantly increased 
pancreatic gene expression of Akt 1 and 2 isoforms 
(Fig.4H), Akt protein levels and AKT activation via 
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phosphorylation (Fig.4I). To test the functional 
relevance of Akt signaling, we administered the 
potent pan-Akt inhibitor MK-2206, which efficiently 
reduces Akt activation in vivo [26]. MK-2206-treated 
mice (treatment scheme depicted in Fig.S5A) showed 
reduced Akt activation (Fig.4J), confirming the 
efficacy of the compound. Importantly, MK-2206 
treatment strongly reduced acinar cell proliferation 
(Fig.4K) and cyclin expression (Fig.S5B) induced by 
T3. Reduced acinar cell proliferation correlated with 
a significant increase in the cell cycle inhibitor 
p15/INK4B and p16/INK4A (Fig.S5C), which could 
likely contribute to the observed inhibition of 
proliferation.  
Collectively, these data demonstrate that T3 promotes 
the proliferation of healthy acinar cells by activating 
signaling pathways known to support acinar 
proliferation in the course of pancreatitis. 
 
Acinar proliferation induced by T3 
administration is restrained by TGF signaling.  
We recently showed that increased levels of 
Transforming Growth Factor beta (TGF) and 
activation of TGF signaling in pancreatic cells by 
TGF receptor II tightly reduces acinar cell 
proliferation during cerulein-induced pancreatitis 
[10], suggesting that TGF signaling belongs to the 
arsenal of negative regulators that control the level of 
pancreatic regeneration. Here we tested whether 
TGF levels increased upon T3 administration 
(scheme depicted in Fig.4A) and whether TGF 
signaling limited the extent of T3-induced acinar 
proliferation also in the absence of an inflammatory 
reaction. 
Expression levels of TGF 1–3 isoforms increased in 
the pancreas at 96h following T3 supplementation 
(Fig.5A). However, increased expression of TGF 
ligands was not accompanied by a robust increase in 
phosphorylation of SMAD effector proteins at this 
time point (Fig.5B), suggesting that activation of 
TGF signaling is blunted by the presence of T3. 
To investigate whether the observed upregulation of 
TGF exerts an anti-mitogenic action, we assessed 
the levels of T3-induced acinar cell proliferation in 
mice lacking TGF signaling following ablation of 
TGF receptor II in the pancreas [10] (scheme 
depicted in Fig.5C). Similar to what we observed 
upon cerulein administration and inflammatory 
injury, acinar proliferation induced by T3 treatment 
increased in the absence of TGF receptor II, as 
quantified by the levels of proliferation markers 
(Fig.5D) and cyclin expression (Fig.S6A). T3 
treatment did not change robustly the expression of 
cell cycle inhibitors (Fig.S6B). Overall, our data 
suggest that the extent of acinar cell proliferation 
induced upon T3 administration is restrained by 
TGFsignaling.  
 
Discussion 
Thyroid hormones play essential roles in the 
embryonic and adult homeostasis across species, by 
regulating the development of several organs, growth 
and metabolic processes [19]. 
Here we showed that thyroid hormone signaling is 
activated during the pathological setting of 
pancreatitis where it promotes pancreatic 
regeneration.  
These findings have important implication for 
translational application in a therapeutic setting, as 
defective or limited pancreatic regeneration is at the 
core of morbidity associated not only with acute 
pancreatitis but also with acinar atrophy and exocrine 
pancreatic insufficiency found in a broader range of 
pancreatic diseases, including chronic pancreatitis, 
diabetes and cystic fibrosis. 
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Our results highlight three major concepts that 
demonstrate the profound effect exerted by thyroid 
hormones in the pathophysiology of pancreatitis. 
Firstly, we showed that levels of F-T3, the 
biologically active form of thyroid hormones, 
transiently increased in the pancreas following 
inflammatory injury. This local hyperthyroidism was 
determined by direct quantification of the hormone in 
the tissue, by organ-specific up-regulation of 
enzymes responsible for thyroid hormone synthesis 
(reported also in a recently transcriptome-based study 
[27]) and by up-regulation of thyroid hormone 
inactivating enzyme deiodinase 3, an accurate 
functional marker of thyroid hormone status [28, 29]. 
The increase of T3 levels in the injured pancreas was 
independent from circulating levels of thyroid 
hormones, which decreased in the initial stages of the 
disease. This suggests that serum hormone levels are 
not a direct measure of the intracellular T3 
availability in the organ. In addition, the transient 
nature of T3 increase in the organ implies that the 
concentration and consequent signaling of the 
hormone is controlled by the activity of both 
activating and inactivating deiodinases engaged in a 
time-dependent manner in the tissue, as further 
supported by our deiodinases expression data.  
Secondly, we revealed that selectively increasing T3 
levels in the pancreas, by reducing deiodinase 3-
dependent T3 inactivation, boosted acinar 
proliferation in the context of pancreatic injury. This 
mitogenic effect was exquisitely acinar-specific, as it 
did not affect replication of non-acinar cells and was 
not accompanied by changes in tissue damage, 
infiltration of inflammatory cells, or trans-
differentiation of acinar cells into ADM. In addition, 
we showed that deiodinase 3 ablation in untreated 
conditions did not increase T3 levels in the pancreas 
nor induced proliferation of acinar cells, suggesting 
that an initial pancreatic damage is necessary to 
trigger local hyperthyroidism and its consequent 
mitogenic effects. 
Thirdly, we demonstrated that manipulating the 
circulating levels of thyroid hormones had a direct 
impact on acinar cell proliferation.  This raises the 
important clinical implication that hypothyroid 
patients may suffer from impaired pancreatic 
regeneration in the context of pancreatitis. This 
potential concern complement previous reports 
showing that low thyroid hormone levels in acute 
pancreatitis patients are a marker for increased 
severity of the disease [30, 31]. 
Collectively, our data showing enhanced acinar 
proliferation induced by both tissue specific and 
systemic elevation of thyroid hormones provide a 
proof of concept for a potential therapeutic target to 
improve organ regeneration. While systemic T3 
administration did not provoke adverse outcomes of 
tissue damage or inflammation (our study and [6, 7]), 
T3 exerts mitogenic effects in different organs. Thus, 
future research should focus on the development of 
therapeutic interventions promoting proliferation of 
acinar cells in a selective manner during the 
regenerative phase of the organ. In this context, our 
data suggest that inhibition of deiodinase 3 activity is 
an appealing target to increase T3 levels locally in the 
pancreas, as its expression was greatly up-regulated 
in the injured organ and its ablation was sufficient to 
increase acinar proliferation. 
An additional focus of our study was to identify 
molecular pathways activated during T3-induced 
acinar proliferation. By using the controlled setting of 
T3 administration in the absence of pancreatitis, we 
demonstrated that T3 triggers the production of 
several signaling molecules, the activity of which 
either promotes or reduces acinar proliferation. This 
array of regulatory mechanisms provides the 
underlining explanation for the fact that T3-induced 
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acinar proliferation is a temporally controlled 
process. Importantly, they revealed that the signaling 
pathways activated by T3 are also crucial in 
regulating acinar proliferation in the context of 
pancreatitis [10, 23, 24], further supporting the 
concept that T3 is a major factor in driving acinar cell 
division upon inflammatory insult. 
Amongst the pathways identified, we discovered that 
T3-induced acinar proliferation is promoted by the 
activity of the epigenetic modifier class I HDACs and 
by Akt signaling. HDACs are known members of the 
thyroid receptor co-repressor complex regulating the 
genomic effects of T3-induced transcription [32], 
while Akt signaling is considered an example of non-
genomic actions of thyroid hormones, which are rapid 
in their onset and independent from nuclear uptake of 
T3 (reviewed in [21, 33]). Thus, the dual activation of 
genomic and non-genomic pathways suggests that 
both modality of T3 signaling are engaged in the 
pancreas to drive acinar proliferation. This is 
consistent with Akt contributing to mediate the 
effects of T3 administration reported in other tissues 
and cells, including skeletal muscle [34], heart [35] 
and fibroblasts [36], suggesting that activation of 
non-genomic actions is a common pathway in T3-
mediated signaling. 
The third signaling pathways we identified in the 
pancreas in response to T3 administration is TGF. 
Interestingly, while TGF isoforms were upregulated 
during T3 treatment, activation of TGF signaling 
was blunted. This in agreement with a previous report 
showing that T3 antagonizes TGF signaling by 
reducing Smad phosphorylation [37]. The functional 
relevance of this signaling inhibition is likely to 
promote acinar proliferation, as defective TGF 
receptor potentiated the mitogenic effect of T3 in 
acinar cells. In this context, it is tempting to speculate 
the existence of a negative feedback loop where 
TGF is upregulated as a consequence of T3-driven 
proliferation and it acts as a repressor of cell division. 
Interestingly, the cross-talk between T3 and TGF is 
not always of antagonistic nature. As an example, T3 
administration activates TGF signaling in 
hepatocellular carcinoma and results in reduced cell 
proliferation [38].  
 
Conclusions 
Based on our collective results, we propose that 
establishment of a time-dependent and tightly 
controlled local hyperthyroidism in the pancreas 
supports acinar proliferation following injury. This 
discovery harbors therapeutic implications and 
highlights the potential of interventional strategies 
based on the modulation of thyroid hormonal signal 
to promote pancreatic regeneration. 
The mitogenic effect exerted by T3 in adult 
pancreatic acinar cells is shared by several tissues and 
cell types, including renal proximal tubular epithelial 
cells [7], heart cells [39], liver cells [40-42]. 
However, a different situation is observed during 
muscle regeneration, where T3 is required to 
differentiate the local population of satellite stem 
cells into mature muscle cells [12]. Similarly, low 
levels of thyroid hormones maintain the renewal 
capacity of oligodendrocyte progenitor cells, while 
their elevation promotes the switch from stem cell 
proliferation to cell differentiation [43]. Intriguingly, 
but not entirely surprisingly given the pivotal role of 
cancer stem cells to self-renew and drive 
tumorigenesis [44], low levels of thyroid hormones 
are required to support the development of different 
malignancies (reviewed in [45]).  
Thus, our results contribute to expand the concept that 
thyroid hormones induce different outcomes in 
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different replicative contexts where they control the 
balance between proliferation and differentiation. 
While this study provides the first insight into 
endocrine regulation of acinar proliferation, further 
studies are required to elucidate fully the details of 
thyroid hormone actions in the pancreas. An open 
question not addressed in our study is the 
identification of the thyroid hormone receptors 
involved in the observed phenotype and the 
characterization of their cistromes in vivo.  This is of 
special interest as the receptor isoforms have different 
repertoires of target genes [46], the expression of 
which can be affected by thyroid hormone binding in 
either a positive or negative manner [47]. 
Another open question concerns the role of 
transmembrane transporters for thyroid hormones 
[48, 49] in regulating hormone availability in the 
pancreas. While a thorough characterization of 
transporter families has not been performed in acinar 
cells, it is worth mentioning that amongst the L-type 
amino acid transporters involved in thyroid hormone 
uptake, Lat1 and Lat2 are expressed on the basolateral 
membrane of adult acinar cells [50]. 
Finally, the investigation of the upstream signals that 
regulate expression of deiodinases in the injured 
pancreas is of major interest. Their identification is 
crucial not only to understand how the onset of local 
hyperthyroidism takes place, but also to identify 
possible targets to exploit as therapeutic intervention. 
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Figure legends 
 
Figure 1. Pancreatic levels of F-T3 increase following cerulein-induced pancreatitis. (A) Schematic 
representation of cerulein (Cer) administration. Mice received six injections daily over two consecutive days. 
Harvest time is indicated as hours after the first cerulein injection. (B) Quantification of acinar cells positive for 
the replication marker Ki67 at the indicated time after cerulein administration. Right panels, representative 
microphotographs of stained cells. (C) Quantification of free T3 (F-T3) in the pancreas at the indicated time after 
cerulein administration. (D) Quantification of free T4 and free T3 in the mice sera at the indicated time after 
cerulein administration. (E) qPCR of deiodinase (DIO) 1-3 in the pancreas at the indicated time after cerulein 
administration. (F) qPCR of deiodinase (DIO) 1-3 in pancreatic acini isolated 24 hours after cerulein 
administration. Right panel, representative microphotographs of isolated acini. (G) qPCR of deiodinase (DIO) 1-
3 in different organs at the indicated time after cerulein administration. Results are average ± SEM (n=5), *P < 
0.05. Scale bars: 50 M. 
Figure 2. Ablation of deiodinase 3 in acinar cells increases acinar proliferation following induction of 
pancreatitis. (A) Schematic representation of conditional deiodinase 3 knocked out breeding. (B) Hematoxylin 
and Eosin (H&E) staining of pancreata in wild type (WT) and deiodinase 3 knocked out (D3KO) mice in untreated 
conditions. (C) Quantification of PU.1-positive inflammatory cells in untreated WT and D3KO mice. Right panels, 
representative microphotographs of stained cells (arrows). (D) Quantification of Ki67-positive acinar and 
interstitial cells in untreated mice. Right panels, representative microphotographs of stained acinar (arrows) and 
interstitial (arrowheads) cells). (E) Quantification of pancreatic and serum levels of free T3 (F-T3) and free T4 (F-
T4) in untreated mice. (F) Schematic representation of induction of pancreatitis with cerulein injections in WT 
and D3KO mice. (G) Quantification of Ki67-positive acinar cells at the indicated time following induction of 
pancreatitis. Right panels, representative microphotographs of stained cells 96h after pancreatitis induction.  (H) 
qPCR of cyclin expression in the pancreas at the indicated time following induction of pancreatitis. (I) 
Quantification of free T3 in the pancreas at the indicated time following induction of pancreatitis. (J) 
Quantification of amylase and lipase activity in serum at the indicated time following induction of pancreatitis. 
(K) Quantification of PU.1-positive inflammatory cells at the indicated time after induction of pancreatitis. Right 
panels, representative microphotographs of stained cells (arrows). (L) Quantification of ADM 96 hours after 
induction of pancreatitis. Right panel, representative microphotograph of ADM area (asterisk). Results are average 
± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure 3. Systemic alteration of thyroid hormone levels affects acinar proliferation following induction of 
pancreatitis. (A) Schematic representation of pancreatitis induction upon hyperthyroidism (i) and hypothyroidism 
(II) with T3 and MMI administration, respectively. (B) Quantification of serum levels of free T4 (F-T4) and free 
T3 (F-T3) 96 hours after induction of pancreatitis. (C) Quantification of Ki67 and pH3-positive acinar cells 72 and 
96 hours after induction of pancreatitis. Right panels, representative microphotographs of stained cells 96 hours 
after pancreatitis induction.  (D) qPCR of cyclin expression in the pancreas at the indicated time following 
induction of pancreatitis. (E) Quantification of Ki67-positive acinar cells 96 hours after induction of pancreatitis. 
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(F) Quantification of amylase and lipase activity in serum at the indicated time following induction of pancreatitis. 
(G) Quantification of Pu.1-positive inflammatory cells at the indicated time after induction of pancreatitis. (H) 
Schematic representation of pancreatitis induction upon IOP treatment. (I) Quantification of serum levels of free 
T4 (F-T4) and free T3 (F-T3) at the indicated time after induction of pancreatitis. (J) Quantification of Ki67 and 
pH3-positive acinar cells at the indicated time after induction of pancreatitis. Right panels, representative 
microphotographs of stained cells 96 hours after induction of pancreatitis.  Results are average ± SEM (n=5), *P 
< 0.05. Scale bars: 50 M. 
Figure 4. T3-induced acinar proliferation is supported by HDAC activity and Akt signaling. (A) Schematic 
representation of T3 treatment. (B) Quantification of Ki67 and pH3-positive acinar cells 96 hours after T3 
treatment. (C) Quantification of Ki67-positive acinar cells 96 hours after T3 treatment at the indicated 
concentrations. (D) Quantification of PU.1-positive inflammatory infiltrating the pancreas 96 hours after T3 
treatment. (E) qPCR of class I and class II HDAC expression in the pancreas 96 hours after T3 treatment. (F) 
Quantification of HDAC activity in the pancreas 96 hours after T3 treatment. (G) Quantification of Ki67 and pH3-
positive acinar cells 96 hours after T3 treatment in the presence of the selective class I HDAC inhibitor MS-275 
(MS). Right panels, representative microphotographs of stained cells.  (H) qPCR of Akt isoform expression in the 
pancreas 96 hours after T3 treatment. (I) Western blot analyses of Akt expression and activation in the pancreas 
96 hours after T3 treatment. (J) Western blot analyses of Akt activation in the pancreas 96 hours after T3 treatment 
in the presence of the selective Akt inhibitor MK-2206 (MK). (K) Quantification of Ki67 and pH3-positive acinar 
cells 96 hours after T3 treatment in the presence of the selective Akt inhibitor MK-2206 (MK). Right panels, 
representative microphotographs of stained cells.  Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure 5. T3-induced acinar proliferation is restrained by TGF signaling. (A) qPCR of TGF isoform 
expression in the pancreas 96 hours after T3 treatment. (B) Western blot analyses of SMAD expression and 
activation in the pancreas 96 hours after T3 treatment. (C) Schematic representation of T3 treatment in wild type 
(WT) and TGF receptor II knocked out mice (KO). (D) Quantification of Ki67 and pH3-positive acinar cells 96 
hours after T3 treatment in WT and KO mice. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
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Supplementary figure legends 
 
Figure S1. (A) Quantification of amylase and lipase activity in serum in untreated mice. (B) Quantification of 
Ki67 and pH3-positive acinar cells in untreated mice, one month after tamoxifen treatment. Right panels, 
representative microphotographs of stained cells.  Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure S2. (A) Quantification of acinar cells positive for the apoptotic marker cleaved caspase 3 96 hours after 
induction of pancreatitis. Right panel, representative microphotographs of stained cell (B) Quantification of acinar 
cells positive for the DNA damage marker pH2AX 96 hours after induction of pancreatitis Right panels, 
representative microphotograph of stained cell.  Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure S3. (A) qPCR of cyclin expression in the pancreas  96 hours after T3 administration. (B) Hematoxylin and 
Eosin (H&E) staining of pancreata 96 hours after T3 administration. Results are average ± SEM (n=5), *P < 0.05. 
Scale bars: 50 M. 
Figure S4. (A) Schematic representation of T3 treatment in the presence of the selective class I inhibitor MS-275 
(MS). (B) Quantification of HDAC activity in the pancreas 96 hours after T3 treatment in the presence of MS. (C) 
qPCR of cyclin expression in the pancreas 96 hours after T3 treatment in the presence of MS. (D) qPCR of cell 
cycle inhibitor expression in the pancreas 96 hours after T3 treatment in the presence of MS. Results are average 
± SEM (n=5), *P < 0.05. 
Figure S5. (A) Schematic representation of T3 treatment in the presence of the selective Akt inhibitor MK-2206 
(MK). (B) qPCR of cyclin expression in the pancreas 96 hours after T3 treatment in the presence of MK. (C) qPCR 
of cell cycle inhibitor expression in the pancreas 96 hours after T3 treatment in the presence of MK. Results are 
average ± SEM (n=5), *P < 0.05. 
Figure S6. (A) qPCR of cyclin expression in the pancreas 96 hours after T3 treatment in wild type (WT) and 
TGF receptor II deficient (KO) mice. (C) qPCR of cell cycle inhibitor expression in the pancreas 96 hours after 
T3 treatment. Results are average ± SEM (n=5), *P < 0.05. 
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Abstract 
Background and Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) are administered to manage pain 
typically found in patients suffering from pancreatitis. NSAIDs also display anti-proliferative activity against 
cancer cells, however their effects in normal, untransformed cells is poorly understood. Here we evaluated whether 
NSAIDs inhibit proliferation of pancreatic acinar cells during the development of acute pancreatitis. 
Experimental Approach The NSAIDs ibuprofen and diclofenac were administered to C57BL/6 mice after 
induction of pancreatitis with serial injection of cerulein. In addition, ibuprofen was administered concomitantly 
to 3,5,3-L-tri-iodothyronine (T3), which induces acinar cell proliferation in the absence of tissue inflammation. 
Development of pancreatic inflammation, acinar de-differentiation into metaplastic lesions and acinar proliferation 
were quantified by histochemical, biochemical and RT-PCR approaches.  
Key Results Therapeutic ibuprofen treatment selectively reduced pancreatic infiltration of activated macrophages 
in vivo, M1 macrophage polarization and pro-inflammatory cytokine expression both in vivo and in vitro. Reduced 
macrophage activation was accompanied by reduced acinar de-differentiation into acinar-to-ductal metaplasia. 
Acinar proliferation was significantly impaired in the presence of ibuprofen and diclofenac, evidenced both at the 
level of proliferation markers and expression of cell cycle regulators. Ibuprofen treatment also reduced acinar cell 
proliferation induced upon mitogenic stimulation with T3, a treatment that does not elicit pancreatic inflammation.  
Conclusions and Implications Our study provides evidence that the NSAIDs ibuprofen and diclofenac inhibit 
pancreatic acinar cell division. This suggests that prolonged treatment with these NSAIDs may negatively affect 
the extent of pancreatic regeneration and further studies are needed to confirm these findings in a clinical setting. 
ABBREVIATIONS 
NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; i.p.. intraperitoneal; T3, 3,5,3-L-tri-
iodothyronine; ADM, acinar-to-ductal metaplasia. 
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INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
a broad family of compounds primarily used as 
analgesics to treat pains of different origin and to 
control inflammation. At the molecular level, 
NSAIDs exert these effects by inhibiting the activity 
of cyclooxygenase 1 (COX1) and cyclooxygenase 2 
(COX2) (Chavez and DeKorte, 2003), enzymes that 
catalyze the synthesis of prostaglandins and 
thromboxanes. In addition to the established and well 
exploited analgesic and anti-inflammatory effects of 
these compounds, numerous studies have 
demonstrated that NSAIDs are also effective in the 
prevention of many common cancers (Taketo, 1998, 
Vainio, 2001). This is particularly evident in the case 
of ibuprofen, the most commonly used over-the-
counter NSAID (Bushra and Aslam, 2010). 
Specifically, this drug showed a superior 
effectiveness compared with other NSAIDs in 
suppressing proliferation and inducing apoptosis of 
human prostate cancer cells at clinically relevant 
concentrations (Andrews et al., 2002). Similar 
inhibition of proliferation exerted by ibuprofen, alone 
or in combination therapy,  was also observed in the 
case of gastric (Bonelli et al., 2011), lung (Endo et al., 
2014), colon (Greenspan et al., 2011, Reddy et al., 
1992) and breast cancer, suggesting that ibuprofen 
may be useful in the chemoprevention of different 
malignancies (reviewed in (Piazza et al., 2010, 
Gurpinar et al., 2014).  
While the anti-proliferative effect of ibuprofen is well 
documented in the case of cancer cells, the impact of 
this drug on the proliferation of normal cells in the 
absence of malignant transformation is poorly 
elucidated. Ibuprofen is amongst the therapeutic 
interventions administered to relief the pain 
characteristic for patients suffering from mild forms 
of acute pancreatitis, or, in the most severe cases of 
the disease, when patients are weaned off narcotic 
therapy.  In addition, it is also used to manage chronic 
pancreatitis, where the permanent inflammation of 
the organ is associated with continuing pain 
(reviewed in (Banks et al., 2010)). NSAID treatment 
has also been shown prophylactic effects to prevent 
post-operative pancreatitis when given prior to 
endoscopic retrograde cholangiopancreatography 
(ERCP) (Murray et al., 2003, Sotoudehmanesh et al., 
2007). Surprisingly, extensive studies to evaluate the 
efficacy of NSAID during acute pancreatitis are 
missing. A recent review of the available literature 
highlighted the fact that, while NSAIDs are able to 
control pain in acute pancreatitis patients, the use of 
NSAIDs is also associated with the risk for 
developing acute pancreatitis (reviewed in (Raffaele 
Pezzilli, 2010)). Thus, further clinical trials are 
needed to identify the optimal NSAID to be used in 
the management of pancreatitis. 
In this study we evaluated whether the therapeutic 
administration of the NSAIDs ibuprofen and 
diclofenac affect the course of acute pancreatitis in 
terms of progression of inflammation and 
regeneration of the organ, using the most widespread 
murine model of the disease based on cerulein 
treatment. In addition, we investigated whether 
ibuprofen, administered in the absence of 
inflammatory insult, is able to directly inhibit 
mitogen-induced proliferation of pancreatic acinar 
cells. 
 
METHODS 
The drug/molecular target nomenclature conforms to 
the BJP's Concise Guide to Pharmacology (Alexander 
et al., 2015). 
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Animal experiments  
All animal experiments were performed in 
accordance with Swiss Federal animal regulations 
and approved by the cantonal veterinary office of 
Zurich. All studies involving animals are reported in 
accordance with the ARRIVE guidelines for 
reporting experiments involving animals. Mice used 
in this study were adult 8–12 week old C57BL/6 mice 
in a weight range of 25-30 g (Envigo Laboratories, 
Horst, The Netherlands). Groups of 4-5 mice were 
kept in standard individually ventilated cages (IVCs) 
in a SPF facility. Only male mice were used in this 
study. Pancreatitis was induced via six intraperitoneal 
(i.p.) injections of 50 g/kg cerulein, at hourly 
interval. In the “staggered” protocol, cerulein 
treatment was performed on three alternate days 
(Monday, Wednesday and Friday) and animals were 
harvested on the following Monday, seven days after 
the initial cerulein injection. In the “consecutive” 
protocol, cerulein treatment was performed on two 
consecutive days (Monday and Tuesday) and animals 
were harvested on the following Monday, seven days 
after the initial cerulein injection. Ibuprofen and 
diclofenac (Sigma) were injected twice daily, two 
hours apart, i.p. at 25 mg/kg and 10 mg/kg, 
respectively. Control animals for cerulein, ibuprofen 
and diclofenac treatments received vehicle (saline 
solution, 0.9% NaCl) injections.  In the “staggered” 
protocol of pancreatitis, ibuprofen was administered 
for five days starting two hours after the second set of 
cerulein injections. In the “consecutive” protocol of 
pancreatitis, ibuprofen and diclofenac were 
administered for five days starting 24 hours after the 
second set of cerulein injections. 
3,5,3-L-tri-iodothyronine (T3) was administered 
daily i.p. at 400 mg/kg. Stock solution of 2mg/mL T3 
were prepared in 0.1M NaOH, pH 7.4 and freshly 
diluted in saline to the final concentration required for 
the in vivo experiments. Control animals received 
vehicle injections. Ibuprofen was injected twice daily, 
i.p. at 25 mg/kg, one hour before and one hour after 
T3 injections. Schematic representations of the 
different study groups are depicted in the relevant 
figures. 
Animal harvest was performed under isoflurane 
anesthesia. Groups of 5 animals were tested for each 
experiment and time point. Animals were assigned 
randomly to different experimental groups for all in 
vivo studies. Data collection and evaluation of all in 
vivo and in vitro experiments were performed blindly 
of the group identity. 
Mammalian cell cultures 
The RAW264.7 macrophage cell line was maintained 
in Dulbecco’s Modified Eagle medium 
(DMEM)+GlutaMAX supplemented with 10% fetal 
bovine serum (FBS), 50 U/mL penicillin, and 50 
µg/mL streptomycin at 37°C in a 5% CO2 
atmosphere. Cells were pre-incubated with 800 M 
ibuprofen for 30 minutes and stimulated with 10 
ng/mL LPS for 16 hours in the presence or absence of 
ibuprofen. 
The AR42J acinar cell line was maintained in F12K 
medium supplemented with 20% fetal bovine serum 
(FBS), 50 U/mL penicillin, and 50 µg/mL 
streptomycin at 37°C in a 5% CO2 atmosphere. For 
proliferation experiments, cells were seeded in 96 
well-plates and incubated with different 
concentrations of ibuprofen for 72 hours.  
Cell number, cell viability and cell diameter were 
determined using an automated cell counter 
(NucleoCounter® NC-200™, Chemometec, Allerod, 
Denmark).   
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Transcript analysis  
Total RNA was extracted from pancreatic tissue, as 
described previously (Graf et al., 2002), or cell lines 
and reverse-transcribed with qScript™ cDNA 
SuperMix (Quanta Biosciences). Gene expression 
was measured by real-time PCR on a 7500 Fast Real-
Time PCR System (Applied Biosystems) using 
Taqman probes (Applied Biosystems). Transcript 
levels were normalized using 18S RNA as a reference 
and expressed as Ct relative to the value of control 
samples.  
Immunohistochemistry  
Pancreas specimens were fixed overnight in neutral 
buffered formalin, dehydrated through a series of 
graded ethanol baths and embedded in paraffin.  For 
histological analyses, 3 m tissue sections were 
deparaffinized in xylol and rehydrated in graded 
ethanol. Following antigen retrieval in citrate buffer 
and neutralization of endogenous peroxidase activity 
with 0.3% hydrogen peroxide in methanol, sections 
were incubated with protein block solution (Dako), 
primary and secondary antibodies and stained with 
3,3′-diaminobenzidine tetrahydrochloride (DAB) 
(Vectastain® ABC HRP Kit, Vector Laboratories, 
Peterborough, UK), according to the manufacturer’s 
protocol. Primary antibodies used in this study were: 
rabbit anti-Ki67 (#ab16667, Abcam, Cambridge, 
UK); rabbit anti-phospho-histone 3 (#2066052, 
Millipore, MA, USA); rabbit anti-amylase (#A8273-
1VL, Sigma-Aldrich, Buchs, Switzerland); rabbit 
anti-PU.1 (#2266, Cell Signaling Technologies, 
Danvers, MA); rabbit anti- H2A.X (Ser139) (#9718, 
Cell Signaling Technologies, Danvers, MA); rat anti-
F4/80 (#T-2006 BMA Biomedicals, Switzerland); 
rabbit anti-CD3 (#A 0452, Dako); rabbit anti-cleaved 
Caspase-3 (Asp175) (#9661, Cell Signaling 
Technologies, Danvers, MA); mouse anti-
YM1/Chitinase 3-like 3 (#AF2446, R&D Systems, 
MN, USA); rabbit anti-IRF-5 (#10547-1-AP, 
Proteintech, Manchester, UK).  
Secondary antibodies used in this study were 
biotinylated goat anti-rabbit IgG (H + L), included in 
the Vectastain® ABC HRP Kit. Nuclei were 
visualized with 4,6-diamidino-2-phenylindole 
(DAPI).  
Detection of DNA fragmentation in apoptotic cells 
was performed with a TUNEL assay using an 
ApopTag peroxidase Kit (MP Biomedicals, Illkirch, 
France), according to the manufacturer’s instructions.  
For quantitative analysis of ADM, paraffin-
embedded pancreas specimens were immunostained 
for amylase, slides were scanned with a NDP 
NanoZoomer Digital Pathology Slide Scanner 
(Hamamatsu) and analyzed for ADM lesions in a 
blinded fashion. ADM present in the entire pancreas 
slide of 5 mice from each treatment condition were 
quantified by manual counting. ADM were identified 
according to: i) loss of amylase content, ii) structural 
re-organization into tubular complexes, iii) stromal 
reaction characterized by presence of cell infiltrates. 
The area occupied by ADM was expressed as 
percentage of total pancreatic area present in each 
slide. 
The amount of amylase and F4/80 expressing 
macrophages present in the tissue was determined by 
densitometric quantification in at least 10 random 
high-power fields per slide using the Cell^P analysis 
software (Olympus). Positive area was expressed as 
percentage of total pancreatic area present in each 
power field. Pancreatic ducts and vessels were 
excluded from the analysis. 
Microscopy analyses were performed on a wide-field 
Nikon Eclipse Ti (Amsterdam, The Netherlands). 
Quantification of labelled cells was performed in at 
least 10 randomly selected high-power fields (×200) 
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per slide using the NIS Elements BR Analysis and 
Cell^P analysis software.   
Data and analysis  
The data are expressed as means ± SEM. The 
statistical significance of differences in the means of 
experimental groups was determined using an 
unpaired, two-tailed Student's t test (GraphPad Prism 
4.0c; GraphPad Software, Inc.) and a probability 
value <0.05 was considered statistically significant. 
Data and statistical analyses comply with the 
recommendations on experimental design and 
analysis in pharmacology (Curtis et al., 2015). 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are 
hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common 
portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Southan et al., 2016), and are 
permanently archived in the Concise Guide to 
PHARMACOLOGY 2015/16 (Alexander et al., 
2015). 
 
RESULTS 
Ibuprofen treatment reduces pancreatic 
recruitment of activated macrophages following 
induction of acute pancreatitis.  
To assess the effect of ibuprofen during the 
progression of pancreatitis, we administered the drug 
in a therapeutic manner starting two days after 
induction of the disease via cerulein injections 
(regimen scheme depicted in Fig. 1A). In this 
experimental setting, the initial acinar injury is 
comparable in the control and ibuprofen-treated 
groups. Ibuprofen was applied at a dose similar to the 
range used in human therapy (Janssen and Venema, 
1985), and which was demonstrated to inhibit 
prostaglandin production and pain perception in mice 
(Salama et al., 2016). Animals were harvested seven 
days after the first cerulein injection. Following 
induction of pancreatitis, ibuprofen-treated mice 
displayed histological alterations of pancreatic 
parenchyma similar to vehicle-treated mice (Fig. 1B) 
and a comparable pattern of weight loss (Fig. S1). We 
then investigated whether ibuprofen reduced the 
infiltration of inflammatory cells. The total number of 
leukocytes was only slightly lowered in the presence 
of the drug (Fig. 1C). However, ibuprofen reduced the 
level of macrophages recruited in the pancreas, tested 
both via F4/80 immunostaining, detecting activated 
macrophages, and gene expression levels (Fig. 1D, 
F). On the contrary, the number of CD3-positive T 
cells was comparable in control and treated samples 
(Fig. 1D, F). These data suggest that ibuprofen targets 
the infiltration of selected sub-populations of 
inflammatory cells. Concomitant with reduced 
macrophage infiltration, ibuprofen treatment also 
reduced the expression of selected cytokines, 
chemokines and adhesion molecules normally up-
regulated in the pancreas following induction of 
pancreatitis (Fig. 1G). To test whether ibuprofen 
directly inhibits macrophage activation and cytokine 
expression, we treated RAW 264.7 macrophages with 
the drug in vitro and quantified their activation upon 
LPS stimulation. RAW cells responded to 16 hours of 
LPS treatment, as evidenced by a change in cell shape 
to a flattened, pancake-like morphology (McWhorter 
et al., 2013) (Fig. 2A), increased cell diameter (Fig. 
2B) and reduced proliferation (Fig. 2C). Ibuprofen 
did not alter these parameters, however, similarly to 
what was observed in vivo, it reduced the expression 
of selected cytokines in LPS-treated macrophages 
(Fig. 2D). This suggests that ibuprofen directly 
counteracts the functional activation of macrophages.  
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Ibuprofen treatment reduces ADM formation 
following induction of acute pancreatitis.  
We then further analyzed the inhibitory effect of 
ibuprofen on macrophages, as these cells play an 
essential role in the context of pancreatitis. Indeed, 
macrophages orchestrate both the initiation and the 
resolution of inflammation (reviewed in (Shrivastava 
and Bhatia, 2010)). In addition, M1 polarized 
macrophages directly influence the status of acinar 
cells, as they can initiate and drive the transient trans-
differentiation of acinar cells into acinar-to-ductal 
metaplasia (ADM), which occurs during the 
regenerative phase of pancreatitis (Liou et al., 2013, 
Liou and Storz, 2015). Specifically, F4/80-positive 
activated macrophages are abundantly found 
associated with ADM lesions, where M1 
macrophages are more abundant than M2 
macrophages (Fig. 3A). Ibuprofen decreased the 
expression of M1 macrophage markers (Cd40, 
iNos2), without altering the levels of M2 macrophage 
markers (Arg1, Clec10) (Fig. 3B). Amongst the 
cytokines secreted by M1 macrophages, TNF and 
RANTES/CCL5 have been previously identified as 
the major inducers of acinar cell reprogramming into 
ADM (Liou et al., 2013). We found that ibuprofen 
treatment limited the expression of both cytokines in 
the pancreas upon induction of pancreatitis (Fig. 3C).   
Finally, we analyzed whether the reduced amount of 
M1 macrophages and ADM-promoting cytokines 
observed in the pancreas following ibuprofen 
treatment was associated with and reduced ADM 
formation. Ibuprofen-treated mice showed a 
decreased trend of mature ADM lesions, 
morphologically defined by loss of amylase 
expression, structural re-organization into tubular 
complexes and stromal reaction with robust cell 
infiltration (Fig. 3D, E), and decreased trend, albeit 
not significant, of the ADM marker CK19 expression 
(Fig. S2). In addition, densitometric quantification of 
amylase levels, which allows the determination of 
tissue with intact acinar cells, showed larger area of 
amylase-expressing acinar cells devoid of ADM upon 
ibuprofen treatment (Fig. 3F). Collectively, these data 
indicate that inhibition of macrophage 
recruitment/function mediated by ibuprofen 
treatment is likely to limit acinar de-differentiation 
into metaplastic lesions following induction of 
pancreatitis. 
Ibuprofen treatment reduces acinar cell 
proliferation following induction of acute 
pancreatitis.  
Adult pancreatic acinar cells have the ability to 
initiate a proliferation program following pancreatitis 
to regenerate damaged tissue. As ibuprofen limits the 
proliferation of different cancer cell types, we tested 
whether the drug also reduced the proliferation of 
untransformed acinar cells. Ibuprofen treatment 
decreased the number of acinar cells expressing the 
proliferation markers Ki67 and phosphor-histone 3 
(pH3) (Fig 4A). Expression of both early and late 
cyclins was also reduced (Fig. 4B). Reduced acinar 
proliferation was not caused by up-regulation of 
cyclin-dependent kinase inhibitors (CDKi). Indeed, 
ibuprofen-treated pancreata showed a general 
decrease in CDKi and p53 expression (Fig. 4C). 
Ibuprofen exerts its anti-proliferative actions on 
several immortalized cell lines, including microglia 
(Elsisi et al., 2005), glioma (Gomes and Colquhoun, 
2012) and  gastric cancer cells (Bonelli et al., 2011), 
through induction of apoptosis. Thus we tested 
whether apoptotic cell death was induced in acinar 
cells upon treatment with the drug. Quantification of 
cleaved caspase 3 (Fig. 4D) and DNA fragmentation 
by TUNEL assay (Fig. S3A) showed that ibuprofen 
did not increase apoptosis of acinar cells in the 
context of pancreatitis. Similarly, ibuprofen treatment 
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did not increase the levels of DNA damage in acinar 
cells (Fig. S3B) or the expression of heat shock 
protein 72 and Bcl2 (Fig. 4E), which exert a 
protective effect against cell death in the pancreas 
(Saluja and Dudeja, 2008). Collectively, these results 
showed that ibuprofen administration reduced acinar 
cell proliferation in the context of pancreatitis without 
engaging a cell death program previously reported in 
ibuprofen-treated cancer cells. 
Finally, we tested whether ibuprofen was effective in 
reducing acinar proliferation when administered after 
the completion of cerulein treatment. To this aim, 
cerulein was applied on two consecutive days 
followed by five days of ibuprofen (scheme in Fig. 
5A). Ibuprofen reduced proliferation of acinar and 
interstitial cells also in this protocol of acute 
pancreatitis (Fig. 5B, C). In addition, similar 
inhibition was achieved by the non-selective COX 
inhibitor diclofenac (Fig. 5A-C), suggesting that 
different NSAIDs share the ability to interfere with 
acinar cell proliferation. 
Ibuprofen treatment reduces acinar cell 
proliferation upon T3-induced mitogenic 
stimulation. 
While our results point out an anti-proliferative effect 
of ibuprofen in the context of pancreatitis, the altered 
inflammatory milieu observed in the presence of the 
drug may constitute a confounding factor that 
prevents the direct assessment of the inhibitory 
properties of ibuprofen in acinar cells. Thus, we 
tested the effect of ibuprofen on acinar cell 
proliferation in an experimental model independent 
from inflammation. To this aim, mice were treated for 
four days with the thyroid hormone 3,5,3-L-tri-
iodothyronine (T3), which acts as a mitogen for 
pancreatic acinar cells (Kowalik et al., 2010, Ledda-
Columbano et al., 2005), concomitantly with 
ibuprofen administration (scheme depicted in Fig. 
6A). As expected, T3 did not induce leukocyte 
recruitment in the pancreas (Fig. 6B) or up-regulation 
of COX enzymes (Fig. 6C). Importantly, ibuprofen 
treatment did not change basal leukocyte levels (Fig. 
6B), but selectively decreased proliferation of acinar 
cells without affecting interstitial cells (Fig. 6D). 
Similar to what was observed in the context of 
pancreatitis, reduction of acinar cell proliferation was 
not associated with increased apoptotic cell death of 
acinar cells (Fig. S4). In a further experiment, we 
tested whether ibuprofen delayed acinar cell division 
resulting in a long-lasting proliferation index. Four 
days after the last T3 administration, acinar 
proliferation was reduced to near base-line levels in 
both groups, suggesting that ibuprofen-treated mice 
responded to T3 withdrawal without residual 
proliferation activity at the time point analyzed (Fig. 
6E, F). 
Collectively, these results show that ibuprofen is a 
bona fide inhibitor of acinar cell proliferation induced 
by T3 stimulation. 
Finally, ibuprofen was also tested in vitro on the 
pancreatic acinar cell line AR42J. Despite their tumor 
origin, these cells are quite unique in retaining 
morphological and functional characteristics typical 
of adult acinar cells, albeit harbouring an unrestrained 
proliferative ability. Similar to what observed in vivo, 
in vitro treatment with clinically relevant 
concentrations of ibuprofen (Andrews et al., 2002) 
reduced the proliferation of AR42J cells in a dose-
dependent manner (Fig. S5). 
 
DISCUSSION 
Current treatment of pancreatitis primarily involves 
supportive therapy, which includes pain relief and 
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prevention of infection (Paisley and Kinsella, 2014, 
Bang et al., 2008). In this context, NSAIDs are 
frequently used in virtue of their analgesic as well as 
anti-inflammatory effects. However, preclinical 
studies demonstrated that NSAIDs are also effective 
in inhibiting the proliferation of a wide range of 
cancer cells in vitro, either alone or in combination 
with other cancer therapies. This is further supported 
by clinical trials demonstrating that long term use of 
NSAIDs, including ibuprofen, significantly reduces 
the risk of colorectal, breast, lung, prostate and gastric 
cancer and inhibits proliferation of cancer cells, 
including glioma, neuroblastoma, bladder cancer 
cells (Ulrich et al., 2006, Johnson et al., 2010, Baron 
and Sandler, 2000, Leidgens et al., 2015, Ikegaki et 
al., 2014, Chai et al., 2015, Fajardo and Piazza, 2015), 
thus increasing the interest for a novel therapeutic 
application of these drugs. However, this observation 
raises the question whether the inhibition of cell 
proliferation mediated by NSAIDs is also observed in 
non-malignant cells, with the consequence that the 
drug treatment results in delayed regeneration of 
tissues following injury. 
In the present study we investigated the effect of the 
NSAIDs ibuprofen and diclofenac in the regeneration 
of pancreatic tissue in vivo following induction of 
pancreatitis. Our results showed that administration 
of these NSAIDs significantly reduced the 
proliferation of acinar cells. Given the anti-
inflammatory properties of ibuprofen, we then 
investigated whether reduced acinar proliferation was 
derived from a reduced inflammatory response. We 
did not observe a general decrease of pan-leukocyte 
infiltration in the pancreas upon ibuprofen treatment. 
However, macrophage levels and pro-inflammatory 
cytokine/chemokine expression were reduced, 
indicating that the drug affected the recruitment of 
selected leukocyte populations and likely their 
activation. This was further confirmed in in vitro 
experiments where ibuprofen treatment hampered 
LPS-induced activation and cytokine expression in 
macrophages. Reduced inflammation may reduce 
inflammation-dependent damage of acinar cells and 
consequently the need of acinar cell proliferation. 
However, this direct correlation was not observed, as 
DNA damage and apoptosis were unchanged in 
acinar cells in the presence of the drug. 
In this context, it is worth mentioning that expression 
of the anti-apoptotic marker Bcl2 was reduced during 
pancreatitis upon ibuprofen treatment. While the 
exact mechanisms of this lower expression are not 
completely defined, it is likely that this phenotype is 
a consequence of reduced inflammation observed 
following NSAID administration, as inflammatory 
mediators have been reported to regulate Bcl2 
expression in various types of cells (Minshall et al., 
1997, Pugazhenthi et al., 1999). However, another 
intriguing possibility is that lower Bcl2 levels reflect 
the reduced proliferation of acinar cells. Indeed, the 
cellular role of Bcl2 is not restricted to regulating 
apoptosis but it also influences cell proliferation by 
restraining entry into the cell cycle and promoting 
quiescence (reviewed in (Cory et al., 2003)). Thus, 
reduced acinar proliferation in the presence of 
ibuprofen may result in reduced Bcls2 induction to 
limit its negative control of cell division. 
 In addition, ibuprofen treatment reduced acinar cell 
proliferation also in an inflammation-independent 
setting, suggesting that the anti-inflammatory and 
anti-proliferative effects are two independent 
outcomes of ibuprofen treatment. On the other hand, 
the anti-inflammatory effect of ibuprofen is likely to 
impact on the formation of metaplastic lesions 
triggered by induction of pancreatitis. In this respect, 
ibuprofen treatment limited pancreatic infiltration of 
M1 macrophages. The critical role of this cell type 
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and their secreted cytokines in the trans-
differentiation of acinar cells into ADM was shown 
recently (Liou et al., 2013). Amongst numerous 
cytokines produced by macrophages, only TNF and 
RANTES/CCL5 were able to drive acinar cell trans-
differentiation through activation of NF-kB activity 
and NF-kB-induced target genes. Importantly, 
expression of these cytokines was also reduced in our 
ibuprofen-treated pancreata, thus likely explaining 
the reduced trend of ADM formation observed upon 
induction of pancreatitis.  
The striking inhibition of acinar proliferation we 
observed upon ibuprofen and diclofenac treatment 
raises the question on the identity of molecular 
mechanisms underlining the phenotype. As the drugs 
target cyclooxigenases (COXs) and consequently 
reduces prostaglandin (PG) synthesis (Rome and 
Lands, 1975), one possibility is that PGs play a direct 
role in promoting cell proliferation.  In support of this 
hypothesis, elevated COX2 activity and PGs 
production have been found in various hyper-
proliferating cancer cells. Importantly, 
overexpression of this enzyme or exogenous 
administration of PGEs resulted in increased 
proliferation of different cancer cells (Sheng et al., 
2001, Wang and Dubois, 2010, Menter and Dubois, 
2012, Gomes and Colquhoun, 2012, Gu et al., 2008), 
indicating that COX2 activity and PGE synthesis are 
able to drive the cellular replicative program. In 
addition, signaling pathways which are often mutated 
and activated during cancer development, including 
Wnt and Ras pathways, have been shown to up-
regulate COX2 expression (Araki et al., 2003), thus 
directly implicating COX2 activity as a key factor 
promoting tumorigenesis and cancer progression.  
However, the reduced acinar cell proliferation 
observed following ibuprofen treatment is likely to 
be, at least partially, independent from COX2 
activity. The key approach to answer this question 
was provided by our analysis of T3-induced acinar 
proliferation, an experimental setting that does not 
trigger the development of an inflammatory response. 
Indeed, we showed that COX2 was not expressed 
during the pronounced proliferation of acinar cells 
induced by T3 administration. Nevertheless, 
ibuprofen treatment reduced T3-induced acinar 
proliferation. In addition, we showed previously that 
pancreatitis is characterized by increased pancreatic 
expression of COX2 but acinar proliferation does not 
robustly decrease upon either genetic ablation or 
selective pharmacological inhibition of COX2 (Silva 
et al., 2011). 
Collectively, these data indicate that ibuprofen limits 
acinar proliferation independently from its anti-
inflammatory effect and that this inhibition of 
proliferation is likely mediated by COX2-
independent mechanisms targeted by ibuprofen. In 
this context, COX-independent effects have been 
evoked also to explain the effectiveness of NSAIDs 
to inhibit cancer cell proliferation (reviewed in 
(Matos and Jordan, 2015)). Accumulating evidence 
that supports this hypothesis includes the fact that i) 
the anti-tumor effects of NSAIDs are typically seen at 
concentrations higher than those required to inhibit 
PGE synthesis (Tegeder et al., 2001, Grosch et al., 
2006) and ii) NSAIDs still have antineoplastic effects 
when used against COX1 and COX2-deficient cells 
(Zhang et al., 1999).  
One concept that emerges from the numerous reports 
describing the anti-proliferative actions of ibuprofen 
and other COX inhibitors in cancer cells is that the 
drug treatment induces cellular death through 
apoptosis. While this effect is undoubtedly important 
for the potential of NSAIDs as anti-cancer therapy, 
induction of cell death may not be a common outcome 
of ibuprofen administration to normal untransformed 
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cells. In fact, we did not detect increased apoptosis in 
the presence of ibuprofen in mice treated with the 
drug alone, following induction of pancreatitis or 
upon mitogenic stimulation with T3. Thus, it is likely 
that ibuprofen reduced acinar proliferation mainly via 
control of cell cycle. In support of this hypothesis, a 
very interesting study cross-examining the effect of 
ibuprofen in different eukaryotic model organisms, 
showed that the drug delays cell cycle progression 
through the G1 phase, in the absence of cancer-related 
pathologies. Importantly, this led to increased 
lifespan conserved in multiple species (He et al., 
2014), even in yeast cells that are devoid of COX 
enzymes (Simmons et al., 2004). Further studies also 
demonstrated that ibuprofen reduced the proliferation 
of non-cancer cells, including endothelial and human 
coronary artery smooth muscle cells (Wiktorowska-
Owczarek et al., 2015, Dannoura et al., 2014), 
 
Conclusion 
Modulation of the immune system has been proposed 
as a valid therapeutic strategy to mitigate the 
inflammatory response and consequently the severity 
of pancreatitis. Our work raised a caveat regarding the 
use of the commonly prescribed anti-inflammatory 
agents ibuprofen and diclofenac as it revealed that the 
drugs exert a significant anti-proliferative effect in 
acinar cells, as demonstrated in both inflammatory 
situation following induction of pancreatitis and non-
inflammatory situation upon T3-induced mitogenic 
stimulation. Given that COX2 inhibitors have been 
reported to impair regeneration in a murine model of 
skin wound (Gourevitch et al., 2014), bone fracture 
healing (Simon and O'Connor, 2007), tendon healing 
(Connizzo et al., 2014), further studies are warranted 
to assess whether the anti-proliferative effect of these 
NSAIDs detected in acinar cells is detrimental for 
regeneration of the injured pancreas. In this regard, 
special interest should be focused not only on long 
term inflammatory damage of the organ in the context 
of chronic pancreatitis, but also on regeneration from 
tissue loss following pancreatectomy. 
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Figure legends 
Figure 1. Ibuprofen treatment reduces macrophage infiltration following acute pancreatitis. (A) Schematic 
representation of ibuprofen treatment using the “staggered” protocol of cerulein-induced acute pancreatitis. Light 
grey boxes represent six intraperitoneal (i.p.) injections of 50 g/kg cerulein (Cer) administered hourly on alternate 
days. Dark grey boxes represent two i.p. injections of 25 mg/kg ibuprofen (Ibu) administered daily four hours 
apart. Black triangle indicates the time of animal harvest, counting from the first cerulein injection. (B) 
Haematoxylin and Eosin (H&E) staining of pancreata after the indicated treatments. (C) Quantification of 
leukocytes, positive for the pan-leukocytes PU.1, infiltrating the pancreas. Right panel, representative 
microphotograph of stained cells. (D) Quantification of F4/80-positive activated macrophages infiltrating the 
pancreas. Right panel, representative microphotograph of stained cells. (E) Quantification of CD3-positive T-cells 
infiltrating the pancreas. Right panel, representative microphotograph of stained cells. (F) qPCR of F4/80 and Cd3 
expression. (G) qPCR of inflammatory cytokines, chemokine and adhesion molecule expression. Results are 
average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure 2. Ibuprofen treatment reduces cytokine expression in LPS-activated macrophages. (A) Microphotograph 
showing morphological alteration and flattened shape (arrows) in RAW264.7 macrophages upon activation with 
10 ng/mL LPS for 16h in the presence of 800 M ibuprofen. (B) Cell diameter of LPS-treated RAW264.7 
macrophages in the presence of ibuprofen. (C) Quantification of live and dead RAW264.7 macrophages treated 
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with LSP in the presence of ibuprofen. (D) qPCR of pro-inflammatory markers in RAW264.7 macrophages treated 
with LSP in the presence of ibuprofen. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure 3. Ibuprofen treatment alters macrophage polarization and reduces ADM formation following acute 
pancreatitis. (A) Staining of F4/80-positive activated macrophages and M1, M2 polarized macrophages in ADM 
lesions (asterisks). (B) qPCR of M1 and M2 macrophage markers in pancreata.  (C) qPCR of ADM-promoting 
pro-inflammatory cytokines. (D) Staining of amylase revealing intact acinar cells (brown areas) and ADM lesions 
with loss of amylase (asterisks). (E) Quantification of ADM areas following amylase staining, expressed as 
percentage of total area. (F) Quantification of intact acinar cell areas following amylase staining, expressed as 
percentage of total area. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 M. 
Figure 4. Ibuprofen treatment reduces acinar cell proliferation following acute pancreatitis. (A) Quantification of 
proliferating acinar cells upon staining with the general proliferation marker Ki67 and with the mitosis-specific 
marker pH3. Right panels, representative microphotographs of stained cells. qPCR of cyclins (B) and cell cycle 
inhibitors (C) in pancreata after induction of pancreatitis. (D) Quantification of cleaved caspase 3 (CC3)-positive 
apoptotic acinar cells after induction of pancreatitis. Right panel, representative microphotograph of stained cells. 
(E) qPCR of Hsp72 and Bcl2 expression in pancreata. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 
M. 
Figure 5. Ibuprofen and diclofenac treatments reduce acinar cell proliferation in a second model of acute 
pancreatitis. (A) Schematic representation of NSAID treatment using the “consecutive” protocol of cerulein-
induced acute pancreatitis. Light grey boxes represent six intraperitoneal (i.p.) injections of 50 g/kg cerulein (Cer) 
administered hourly on two consecutive days. Dark grey boxes represent two i.p. injections of 25 mg/kg ibuprofen 
(Ibu) administered daily four hours apart. Black boxes represent two i.p. injections of 10 mg/kg diclofenac (Dic) 
administered daily four hours apart. Black triangle indicates the time of animal harvest, counting from the first 
cerulein injection. (B) Quantification of proliferating acinar cells upon staining with the general proliferation 
marker Ki67 and with the mitosis-specific marker pH3. (C) Quantification of proliferating interstitial cells upon 
staining with the general proliferation marker Ki67 and with the mitosis-specific marker pH3. Right panels, 
representative microphotographs of stained cells. Results are average ± SEM (n=5), *P < 0.05. 
Figure 6. Ibuprofen treatment reduces acinar cell proliferation following mitogenic stimulation. (A) Schematic 
representation of ibuprofen treatment during stimulation with 3,5,3-L-tri-iodothyronine (T3). Light grey boxes 
represent daily intraperitoneal (i.p.) injections of 400 mg/kg T3. Dark grey boxes represent two i.p. injections of 
25 mg/kg ibuprofen (Ibu) administered daily four hours apart. Black triangle indicates the time of animal harvest, 
counting from the first T3 injection. (B) Quantification of PU.1-positive pan-leukocytes infiltrating the pancreas. 
(C) qPCR of Cox1,2 expression in pancreata. (D) Quantification of proliferating acinar and interstitial cells upon 
staining with the general proliferation marker Ki67 and with the mitosis-specific marker pH3. (E) Schematic 
representation of prolonged ibuprofen treatment after stimulation with 3,5,3-L-tri-iodothyronine (T3). Symbols 
are as in (A). (F) Quantification of proliferating acinar cells upon staining with the general proliferation marker 
Ki67 and with the mitosis-specific marker pH3. Results are average ± SEM (n=5), *P < 0.05. 
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Supplementary figure legends 
 
 
Supplementary figure 1. Quantification of weight loss, expressed as percentage of initial weight, in mice upon 
induction of acute pancreatitis. Results are average ± SEM (n=5), *P < 0.05. 
Supplementary figure 2. qPCR of ADM marker Ck19. Results are average ± SEM (n=5), *P < 0.05. 
Supplementary figure 3. (A) Quantification of TUNEL-positive apoptotic acinar cells after induction of 
pancreatitis. Right panel, representative microphotograph of stained cells. (B) Quantification of DNA damage in 
acinar cells upon γH2A.X staining after induction of pancreatitis. Right panel, representative microphotograph of 
stained cells. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 µM. 
Supplementary figure 4. Quantification of cleaved-caspase 3 (CC3)-positive apoptotic 
acinar cells following mitogenic stimulation with T3. Results are average ± SEM (n=5), *P < 0.05. 
Supplementary figure 5. Quantification of live cell number after incubating AR42J acinar cells with different 
concentrations of ibuprofen for 72 hours. “Seeded” indicates the initial number of seeded cells. Results are average 
± SEM (n=3), *P < 0.05. 
 
Figure S1 
 
Figure S2 
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Figure S3 
 
 
Figure S4 
 
 
Figure S5 
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6. Discussion 
 
Acute pancreatitis is a debilitating inflammation of the pancreas, which in its severe form is associated with 
substantial morbidity and mortality. Following pancreatitis, the pancreas has some regenerative capacities and 
differentiated acinar cells are able to re-enter the cell cycle and start to proliferate. However, the extent of 
pancreatic regeneration is limited; therefore elucidating the molecular mechanisms that drive pancreatic 
regeneration and boost this process is a major focus of our research. Thyroid hormones are pleiotropic factors 
involved in a variety of cellular processes that range from metabolism to regeneration. Here I will discuss our 
findings about the regulation and function of thyroid hormones during pancreatic regeneration (manuscript A). 
Furthermore, I will integrate in the discussion the results obtained using T3 as a mitogenic stimulus to study the 
mechanisms of acinar cell proliferation in the absence of inflammatory injury (Manuscript B, [166]). 
 
6.1 Local regulation of TH signaling  
 
One of the key aspects of TH signaling is the possibility to be activated in a cell specific fashion independently 
from systemic levels within the circulation. This regulation relies on the differential expression and activity of TH 
transporters and deiodinases enzymes, which define intracellular concentrations of TH. Many studies have 
highlighted that control of local TH availability constitutes an efficient mechanism to modulate cellular responses 
in the context of development, homeostasis and regeneration. In the present project, we sought to investigate 
whether acute pancreatitis alters local availability of TH in both a systemic and tissue specific manner. To this 
aim, we took advantage of the well establish model of serial cerulein injections to induce pancreatitis and 
quantified the levels of TH at different time points.  
Our study design focuses on a one-week period that comprises the induction of damage to the recovery of 
pancreatic tissue, showing kinetics of disease development in line with previously reported observations. We can 
divide this process in the following phases, which in turn help us define and characterize pancreatic regeneration 
following acute pancreatitis (see figure 9): 
1. Induction of damage: Cerulein treatment induces pancreatic damage by overstimulating secretion of 
digestive enzymes that are aberrantly released within the tissue and in the blood. Within the pancreas, 
premature activation of digestive enzymes leads to cell death and necrosis of the tissue. This process 
can be monitored by measuring the amount of digestive enzymes within the circulation as an indicator 
of the pancreatic damage. 
2. Inflammation of the pancreas: consequent to the induction of damage, infiltration of inflammatory cells 
can be observed within the pancreatic tissue.  
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3. Regeneration: beginning about 48h from the first cerulein injections, a wave of acinar cell proliferation 
can be observed. Concomitantly, injured acinar cells may dedifferentiate and acquire a ductal 
phenotype (ADM). 
4. Recovery: one week from the induction of pancreatitis, the pancreatic tissue appears normal with no 
signs of damage and inflammation; furthermore, proliferation returns to baseline values. 
 
Figure 9: Phases of acute pancreatitis. In the present graph the quantification of leucocytes infiltrating cells 
(Pu.1+ cells – left axis) and the number of proliferating acinar cells (Ki67+ - right axis) observed following cerulein 
treatment are presented. See above for a short description of the four phases proposed. To note, the following 
phases were chosen arbitrarily to help the discussion of the obtained results. 
 
We demonstrated that, following induction of damage, acinar cells are able to increase the levels of T3 within 
the pancreas. Importantly, this local hyperthyroidism precedes the beginning of the regenerative phase, offering 
a first hint on the putative involvement of TH in the regeneration of the pancreas. To validate and further 
investigate the observed regulation of TH, we characterized expression levels of deiodinases enzymes, which 
were in agreement with a local activation of TH.  
Similarly to what we observed in the pancreas, TH are locally regulated in response to injury in various organs 
(Heart [167], Liver [168], Muscle [100, 101, 169]). Kester and coworkers for example, observed a regulation of 
deiodinases activities and TH levels in the liver following partial hepatectomy (a model of liver resection to study 
liver regeneration) [168], while Dentice and collaborators described the specific regulation of TH availability 
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within muscle progenitor cells (satellite cells) during skeletal muscle regeneration [100, 101, 169]. In this view, 
TH signaling may serve as a conserved regulator of tissue damage response. It should be restated that, due to 
the intricate network of biological processes regulated by TH, further studies are required to validate this 
hypothesis. 
An interesting topic for future investigation is the identification of the factors that promote activation of TH 
signaling within the pancreas in response to acute pancreatitis. This is of particular interest for the 
characterization of the initial events that trigger pancreatic regeneration. Some of the factors known to promote 
DIO2 upregulation in multiple cellular contexts (i.e. Ca2+/cAMP [65] , NFκB [170], Jnk [171]) have been reported 
to be upregulated at the onset of pancreatitis (Ca2+/cAMP [172] , NFκB [173], Jnk [174]) and may therefore be 
involved in this process during pancreatic regeneration. Of note, the identification of the master regulators of 
pancreatic regeneration, which activate TH following acute pancreatitis, may provide novel means for the 
development of strategies to specifically modulate TH signaling within the pancreas. 
Interestingly, in our model as in liver regeneration [168], induction of tissue injury leads to a decrease in 
circulating levels of TH. This pancreatitis-associated hypothyroidism has also been observed in humans [175]. 
More so, many reports have highlighted that patients hospitalized in intensive care units suffering from acute 
critical illnesses show decreased TH levels within the first hours [176, 177]. Furthermore, Abliz and coworkers 
observed that severe acute pancreatitis in rats induces inflammation of the thyroid, highlighting a direct 
association between pancreatic injury and thyroid status [178]. Although still poorly investigated, a possible 
explanation for this transient hypothyroidism may be ascribed to the increased consumption of TH within the 
injured tissue.  The recognition of a direct link between pancreatitis and thyroid function is of interest because 
severe acute pancreatitis can lead to multi-organs dysfunction and hypothyroidism may be a contributing factor 
in the developing of those complications.  
 
6.2 Effect of TH on pancreatic regeneration 
 
Based on the observed regulation of TH signaling in response to acute pancreatitis, we decided to investigate the 
effect of TH during pancreatic regeneration. To this aim, we used established models of alteration of TH levels as 
well as GMO mice with pancreas specific increase of TH, and characterized pancreatic regeneration following 
acute pancreatitis.  
We demonstrated a positive correlation between TH levels and the number of proliferating acinar cells, which 
provides an indication of the extent of pancreatic regenerative potential. These results are in agreement with 
previously reported observations that exogenous administration of T3 strongly stimulates acinar cell 
proliferation [86, 96, 165]. Moreover, supported by the characterization of the effect of systemic hypothyroidism 
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and peripheral inhibition of TH conversion, we proposed that local hyperthyroidism is an initiating event required 
for the induction of the regenerative phase following acute pancreatitis.  
Interestingly, both in the liver [91] and in the pancreas, administration of T3 during the disease state induces 
more proliferation than observed in healthy conditions. This synergistic effect may account for external signaling 
promoting cell proliferation, as suggested in the liver [91], but may reflect also a more permissive cellular status 
towards increased TH activity.  
No differences in the induction of damage were observed in any of the models used, demonstrating the absence 
of interference between alteration of TH levels and cerulein treatment. Although we did not characterize if 
changes in TH levels affect immunomodulatory properties of infiltrating cells, we did not observe any differences 
in the levels of inflammatory cell infiltration in any of the experimental groups, suggesting that TH do not alter 
the recruitment of infiltrating cells within the pancreatic tissue. This is of interest because previous studies 
highlighted that inflammatory cells are targets of TH activity [179, 180]; however, when TH function is studied in 
the context of regeneration, no changes in the inflammatory response were reported [82, 91, 93, 100, 101, 181]; 
therefore further investigation are needed to better characterize this process.  
Apart from the actions of TH on immune cells, an additional topic for future investigations might be the role of 
inflammation in regulating TH signaling. Most of, if not all, the regenerative responses which show involvement 
of TH are in fact characterized by an inflammatory state of the tissue. In our model for example, recruitment of 
inflammatory cells partially overlaps with the increase in T3 concentration within the pancreatic tissue. 
Understanding whether inflammation is not a prerequisite for regeneration (defined as proliferation of acinar 
cells) may have important consequences in the development of novel therapies.  
 
6.3 Molecular mechanisms of TH action 
 
Taking into account the observed requirement of TH for pancreatic regeneration, we decided to investigate the 
molecular mechanisms of the T3-driven induction of acinar cell proliferation. To be able to focus solely on TH 
action, we supplemented T3 in the absence of an inflammatory reaction.  
We found that T3-driven acinar cell proliferation involves activation of epigenetic modulators (HDACs) and the 
protein kinase B (PKB, also known as Akt), while TGF-β signaling acts as a negative regulator of TH induction of 
proliferation (Manuscript A). These targets were selected based on two selection criteria: 1) previous reports of 
interplay with TH signaling and 2) known activation within the pancreas following acute pancreatitis and 
involvement in acinar cell proliferation. Interestingly, we observed that inhibition of each of the investigated 
pathways affects acinar cell proliferation similarly in the disease state or upon T3 stimulation. This in turn 
suggests that exogenous T3 administration mimics acinar cell proliferation induced by pancreatitis.   
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TH regulate many responses in a cell specific manner, therefore comparison of TH role in the regeneration of 
different organs is difficult.  Nevertheless, we can try to highlight similarities while comparing organs that 
respond to TH. As previously mentioned in the introduction of this thesis, examples of organs in which TH 
stimulate proliferation are liver, skin, and to a certain extend the heart [81, 86, 182]. The Pi3k/Akt signaling 
cascade is amongst studied signaling in regenerative processes and regulates proliferation in many tissues; its 
crucial role in liver regeneration has been demonstrated [183] but evidences that TH can activate this signaling 
in hepatocytes have not yet been provided. Analogously, Pi3k/Akt signaling was demonstrated to participate in 
skin and heart regeneration [184, 185]; with regards to the skin, indirect indications that TH may modulate this 
pathway in keratinocytes come from the analysis of GMO lacking both TH receptors, which showed different 
levels of phosphorylated-Akt compared to Wt [80]. In the heart, Kenessey and Ojamaa demonstrated that T3 
activates the Pi3k/Akt cascade in a TH receptor α1 dependent mechanism, while Mourouzis and coworkers 
highlighted that T3 stimulation of Akt phosphorylation is dose dependent [186, 187].  
The TGF-β signaling, which we demonstrated to act as a restrictor of acinar cell proliferation following acute 
pancreatitis [151] and upon mitogenic stimulation (Manuscript A), is a well known regulator of pancreatic 
regeneration. Particularly, its function is often studied when damage persists and tissue fibrosis occurs. In line 
with our observations, the antagonism between TH and TGF-β signaling has been observed at multiple levels in 
various tissues: for example, TH receptor β is able to inhibit SMAD dependent transcription (a downstream 
effector of TGF-β), reducing liver fibrosis [188], while TGF-β blocks TH action by promoting expression of 
deiodinase type-III in lung fibroblasts and other cells [189]. Interestingly, TGF-β can impair muscle regeneration 
by inhibiting differentiation of myoblasts [190]. It is tempting to speculate that this effect of TGF-β relies on the 
persistent expression of deiodinase type-III. As previously mentioned, deiodinase type-III is upregulated in 
skeletal muscle progenitors while they proliferate and its repression is required to promote TH-driven myofibers 
differentiation [100, 101]. In addition, Safer and colleagues observed divergent effects of TH on skin proliferation 
based on the route of administration. Briefly, while topical application of T3 induced keratinocytes proliferation, 
systemic administration of T3 (injected intraperitoneal) reduced dermal thickening and proliferation. The authors 
proposed that the reduction in proliferating keratinocytes, observed when T3 was administered systemically, 
could be attributed to increased production of TGF-β by the dermal fibroblasts [81]. 
It is important to mention that previously, Kowalik took advantage of a selective agonist for the TH receptor β 
isoform (GC-01) and highlighted that T3-induced mitogenic stimulation of pancreatic acinar cells (and liver 
hepatocytes) is dependent on TH receptor β [96]. In our analysis we did not address the relative contribution of 
TH receptors or other partners, therefore the results presented should be seen as a “generic” TH response.   
Overall, further analyses are required to better understand the similarities or the differences between TH 
modulation of these pathways in different tissues.  
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6.4 The use of TH to study acinar cell proliferation in vivo 
 
While endogenous T3 is required for pancreatic regeneration following pancreatitis, its exogenous 
administration to healthy mice offers a unique model to study acinar cell proliferation in vivo. In the following 
paragraph I will discuss the potential use of this model starting from examples already performed by our lab. 
Pancreatic regeneration includes damage, inflammation, and the participation of multiple cells populations. 
Considering the intricate network of interactions within and amongst the cells, the possibility to discriminate the 
contribution of a selected target to a specific trigger (i.e. damage, inflammation etc.) remains difficult. In this 
view, TH administration may constitute an efficient model to dissect the relative contribution of a selected target 
with regards to acinar cell proliferation without considering damage or inflammation. Indeed, our data 
demonstrated that TH administration, both in healthy condition and during pancreatitis, promotes acinar cell 
proliferation in vivo without inducing damage or inflammation.  
Our lab took advantage of the mitogenic properties of TH to test the effect of selected targets on acinar cell 
proliferation. In manuscript B for example, we investigated the effect of a nonsteroidal anti‐inflammatory drug 
(NSAID), Ibuprofen, on pancreatic regeneration following acute pancreatitis. Ibuprofen is commonly 
administered to patients suffering from mild cases of acute pancreatitis to relieve abdominal pain. To mimic this 
situation, we administered Ibuprofen to mice in a therapeutic regimen following induction of pancreatitis, and 
we analyzed putative changes in the inflammatory and the regenerative responses. We found that Ibuprofen 
treatment reduced both the level of inflammation and the number of proliferating acinar cells. To test if the 
reduction of acinar cell proliferation was a consequence of reduced inflammation, we stimulated acinar 
proliferation with T3 with or without Ibuprofen. Our results demonstrated that Ibuprofen reduces proliferation 
independently of inflammation. The observation that Ibuprofen directly affects pancreatic acinar cell 
proliferation is of clinical interest because it highlights an undesirable side effect. This in turn provides an example 
of putative implementation for the “T3-model” to test potential side effects of therapeutic compounds with 
regards to acinar cell proliferation.  
Similarly, we adopted an analogous approach when studying the effect of Serotonin in pancreatic regeneration 
following pancreatitis [166]. Briefly, we wanted to characterize if absence of peripheral Serotonin (mice lacking 
of tryptophan hydroxylase 1, TPH-KO) altered acinar cell proliferation; to this aim we administered T3 to WT and 
KO mice and compared the number of proliferating acini. Thanks to this model, we could demonstrate that 
absence of peripheral Serotonin does not influence acinar cell proliferation upon T3 stimulation. More so, we 
exploited the “T3-model” to also investigate differences in acinar cell proliferation between mouse strains. 
Particularly, we compared the MRL/MpJ mouse strain to the common B6 response to pancreatitis (paper under 
revision). We observed that following induction of acute pancreatitis, MRL mice had a greater inflammatory 
reaction and higher number of proliferating acinar cells. However, when compared by T3 stimulation, both 
strains showed comparable degree of proliferation; in turn, thanks to the use of T3 we could demonstrate that 
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other factors, and not acinar cells per se, are responsible for the higher regenerative response observed in the 
MRL strain. 
 
6.5 Limitation to the study 
 
The present project aimed to characterize the putative involvement of TH in an experimental model of pancreatic 
regeneration. In this view, the major limitation of the study is possibly the absence of a reporter-based system 
for tracking thyroid hormone status at a cellular level. Indeed the presence of a reporter would have allowed 
gaining more insight on many processes, such as: 
1. Investigate if local hyperthyroidism is a shared event among acinar cells in response to pancreatitis or 
only selected cells modulate TH levels 
2. Confirm that hyperthyroid acinar cells proliferate 
3. Investigate the TH status of other pancreatic cells (i.e. ductal or endocrine cells) 
Importantly for future research, a TRE-luciferase knock-IN mouse model has recently been generated [191]. This 
model will allow monitoring TH receptors transcriptional activity and test genomic action of T3 in vivo. 
Additionally, in the present project we focused our analysis on pathways known to be potentially regulated by 
T3, in this regard the use of –omics approaches may unveil novel targets of TH within the pancreatic tissue. 
Furthermore, here we characterized the effect of acinar specific deletion of deiodinase type-III, the main 
inactivator of TH. Therefore, future studies should focus on the role of type-I and type-II deiodinase in pancreatic 
regeneration. The generation of an acinar-specific KO model for the two deiodinases will in turn provide a tool 
to study the relative contribution of each enzyme in generating a transient local hypothyroidism at the onset of 
acute pancreatitis. 
Lastly, future studies are needed to investigate the importance of TH in other models of pancreatic damage, such 
as pancreatectomy and chronic pancreatitis. 
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7. Conclusive remarks 
 
Our findings highlight an important role of thyroid hormones in promoting acinar cell proliferation 
following acute pancreatitis. Many aspects of TH function within the pancreas remain elusive and offer 
inspiration for further studies. An intriguing observation that emerged is the striking similarity between 
pancreatic and liver with regards to TH mitogenic activity and the dynamics of regeneration. It would 
be interesting to investigate whether a transient local hyperthyroidism occurs during liver 
regeneration; however considering the high expression of deiodinase type I within the liver the 
mechanisms beyond may be remarkably different. Furthermore, our study provide the foundation for 
the development of novel therapies that aim to boost exocrine regeneration. Finally, we propose the 
use of T3-mitogenic activity for the study of the effect of potential therapeutics on acinar cell 
proliferation. 
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